CHAPTER 10

MALIGNANCY

INTRODUCTION

Background

Cancer is a major suspect disease following exposure to chlorophenols, phenoxy herbicides, and dioxin. Both systemic cancer and skin cancer are key focal points of this study.

The issue of military service-related cancer in Vietnam veterans first arose in 1978-1979. Media presentations emphasized early cancer deaths in several Army veterans, which were allegedly caused by exposure to Agent Orange. The media reinforced this perception of increased cancer risk by citing animal studies, which demonstrated a carcinogenic effect, and a few human studies, which showed excessive cancer in specific occupational groups.

Traditional difficulties in extrapolating animal data to humans and interspecies variability have limited the direct applicability of much of the experimental work. Other major challenges have included difficulties in the ability to control or characterize bias; selection of suitable controls or reference groups; quality and quantity of exposure; misclassification of exposure; confounding exposure to known injurious chemicals; sample size and statistical power; number and selection of relevant risk factors; and the lack of clearly defined clinical endpoints for study.

For these reasons, there is no scientific consensus on the dioxin-cancer question. There is, however, concern over soft tissue sarcomas (STS) and non-Hodgkin's lymphoma (NHL).

Numerous animal studies have been conducted to delineate the role of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on tumor initiation, tumor promotion, mutagenesis, cocarcinogenesis, and deoxyribonucleic acid (DNA) reactivity. The consensus of most research is that TCDD is only weakly mutagenic, does not covalently bind to DNA or cause it to initiate repair synthesis, and behaves as a strong tumor promoter in already initiated cells.[1] Recent animal studies have supported the theory that TCDD-induced response is mediated by a nongenotoxic mechanism. TCDD, binding to the Ah receptor, appears to alter cellular regulatory mechanisms that are reflected by enhanced cellular proliferation.[2-6]

The oncogenic response to TCDD in animals has been repeatedly shown to depend upon animal species and strain, dose, age, sex, and route of administration.[7] Conventional skin bioassays in mice produced mixed results in some studies[7,8] but caused significant dermal fibrosarcomas in other studies using different strains of animals.[9] In the presence of a strong carcinogen, TCDD induced skin papillomas in homozygous hairless mice (but not in the heterozygous strain), clearly supporting the promoter role of TCDD, a non-genetic mechanism judged to be related to receptor binding.[10]

Ingestion studies in several rat strains at doses of 0.07-0.1 µg/kg/day produced hepatocellular carcinomas, squamous cell carcinomas of the oropharynx and lung, and follicular cell thyroid adenomas.[11,12] In two mouse strains, gavage doses of 0.07-0.3 µg/kg/day produced hepatocellular carcinomas and thyroid tumors.[12] In the presence of partial hepatectomy and diethylnitrosamine, subcutaneous TCDD administration to rats resulted in hepatocellular carcinomas, demonstrating the promoter mechanism of TCDD.[13] TCDD has been shown to affect the action of estrogen in a number of tissues, possibly leading to carcinogenesis. In rats, TCDD has been shown to promote liver cancer but to inhibit uterine and mammary tumors due to interference with estrogen activity.[14,15] Evidence has also been shown in human cancer cells that TCDD exhibits antiestrogenic activity.[16-18]

Based upon these and other studies, the International Agency for Research on Cancer designated TCDD as carcinogenic in 1982. There are insufficient data to implicate 2,4-D and 2,4,5-T as carcinogens. The majority of animal studies have shown increased risk for carcinomas rather than sarcomas, the tumor type of concern in some human studies.

In a series of publications beginning in 1974, commonly known as the "Swedish studies," extensive inquiry was made into occupational cancer following exposure to a variety of herbicides. Four related efforts[19-22] using Swedish railroad workers found an increased cancer incidence mostly associated with non-TCDD herbicides. However, a case-control analysis of these data by other investigators suggested cancer promotion following phenoxy acid exposure.[23]

Prompted by a slight increase in STS in the railroad workers and clinical experience with a case series of STS, Hardell and coworkers launched an extensive second round of studies.[24-32] These efforts showed statistically significant increased risks for STS, Hodgkin's Disease, and NHL. For exposure to phenoxy acids alone, the risk ratio ranged from 5.3 to 6.8 for STS in northern and southern Sweden, respectively, while a range of 3.3 to 6.6 was noted for exposure to chlorophenol alone. For malignant lymphoma (Hodgkin's Disease plus NHL), risk ratios of 8.4 and 4.8 were respectively demonstrated for chlorophenol and phenoxy acid exposures. An association of nasal and nasopharyngeal cancer to chlorophenol exposure (risk ratio, 6.7) was also detected,[30] but other specifically focused studies of primary liver cancer and colon cancer were negative with respect to phenoxy acid or chlorophenol exposure.[29,31] The colon cancer study was conducted specifically to demonstrate a lack of respondent bias to "validate" previous questionnaire and interview methods used in the STS studies.

From the outset, the Swedish studies have been criticized on methodologic issues,[33-35] prompting the primary authors, Axelson and Hardell, to respond with clarifications, new calculations, amplifying studies on additional cohorts, and studies on other cancers.[29,32,36-38] The chief criticisms centered upon possible respondent and observational biases, selection of controls, confounding exposures, and degree of true exposure to phenoxy acids and chlorophenols. The authors answered these criticisms within the inherent constraints of the case-control methodology. Their efforts have been characterized as careful, clever, and properly stated, and have received favorable reviews.[39,40]

Four small industrial mortality studies were conducted in the late 1970's and early 1980's.[41-44] National Institute for Occupational Safety and Health investigators pooled the data from these studies and noted that 3 of the 105 deaths in these studies were due to STS, as contrasted to an expected 0.07 percent in the U.S. general population.[45] This study has been criticized for the addition of possibly noncomparable industrial cohorts, and the lack of histologic confirmation of the STS cases. A subsequent case report added another STS case to the industrial studies,[46] and two other reports revealed three unrelated STS cases also arising from the industrial sector.[47,48] However, upon closer inspection, only two of the first four cases were confirmed as STS by an independent histologic review.[49] Other reviews of the seven total cases were noteworthy: there was poor agreement on the histologic subtype of the soft tissue tumors, and because of a feature of the International Classification of Diseases (ICD) System, wherein organ-specific sarcomas are coded separately from soft and connective tissue tumors (ICD 171), death certificate-based studies underascertain STS by approximately 40 percent.[49,50] This latter problem did not affect the Swedish studies. Two studies of workers from Dow's Midland facility have indicated slightly increased levels of some (primarily soft-tissue) cancers, but none of statistical significance.[51,52] A study of workers exposed during a 1953 accident at a BASF plant in Germany also showed no statistically significant increases in cancers, but this effort may have suffered from an insufficient cohort size.[53]

Other cancer studies throughout the world showed mixed support for the Swedish findings. An Italian case-control effort[54] showed a weak association between ovarian mesothelial tumors and herbicide exposure, whereas a Finnish study of a small number of pesticide sprayers understandably did not detect any cases of STS or malignant lymphomas (ML).[55] A study of more than 4,000 Danish phenoxy herbicide workers noted five STS cases (vs. 1.8 expected) and seven ML cases (vs. 5.4 expected).[56] The author concluded that the STS observation supported the Swedish work and that the ML data did not.

One New Zealand case-control study showed a nonsignificant relative risk of 1.3 for STS among occupations consistent with phenoxy herbicide exposure,[57] although a risk of 7.2 was noted for STS and potential chlorophenol exposure in tanneries.

A related cancer registry-based case-control study revealed significant excesses of agricultural and forestry occupations from ML cases and multiple myeloma cases (odds ratio 1.25).[58] A recent (1987) expanded version of this study found no increases of risk of NHL and no trend toward increasing risk with increasing duration and intensity of exposure.[59] In a similar but larger cancer registry study in Sweden, there was no increased risk of STS (relative risk 0.9) in agricultural or forestry workers as contrasted to other industrial workers.[60] Further, the STS risk was constant over time in spite of increased usage of phenoxy acid herbicides from 1947 to 1970.

A recent U.S. case-control study from the Kansas cancer registry has provided partial support for Hardell's observations.[61] The Kansas study was very similar in methodology to the early Swedish studies. An overall relative risk of 1.6 was found for NHL in men exposed to herbicides, particularly 2,4-D. As the frequency of herbicide exposure increased to more than 20 days per year, the relative risk of NHL increased to 6.0 as compared to nonfarmers.

For herbicide applicators, the relative risk for NHL was 8.0. A simultaneously published review of the Kansas work noted that this should shift scientific concern from STS to NHL.[62] A population-based case-control study of STS and NHL in western Washington found no overall increased risk of these diseases associated with an occupational history of exposure to chlorophenols or phenoxy herbicides.[63] However, risks of NHL were significantly elevated in the specific occupational categories of farmers, forestry herbicide applicators, and those individuals potentially exposed to phenoxy herbicides in any occupation for 15 years or more. An increased risk of NHL was also noted among those with occupational exposure to insecticides, organic solvents, lead, and welding fumes.

A number of Vietnam veteran studies have attempted to determine whether veterans have experienced excessive mortality, particularly from cancer.[64-71] Most of the studies used proportionate mortality ratio (PMR) methodology and equated Vietnam service with potential exposure to Agent Orange, a procedure of considerable imprecision (misclassification). These exposure allocation difficulties, coupled with the inherent methodological weaknesses of the PMR technique, have minimized the contribution of these studies to the clarification of the cancer issue. As might be predicted, almost all of the studies of veterans were negative for aggregate cancer associations, as well as for STS, Hodgkin's Disease, and NHL associations. As an example of the veteran studies, the Australian retrospective cohort mortality effort revealed an overall relative mortality ratio of 0.99, an overall cancer mortality ratio of 0.95, and nonsignificant statistical differences for STS, NHL, and Hodgkin's Disease.[67] In a recent Vietnam experience study of STS using the case-control method, no significant association was found between military service in Vietnam and the subsequent occurrence of STS.[72]

No consistent pattern for other cancer types has emerged. None of the leukemias has been associated with exposure to Herbicide Orange nor any of its constituents. Two studies noted increases in gastric cancer[22,73] and two others cited modest risks for lung cancer.[74,75] A recent Swedish study reported slight excesses of rectal cancer in male workers and increased cervical cancer from an exposed female cohort.[56]

From another perspective, if exposure to 2,4-D or dioxin causes an immunologic deficiency (see Chapter 19), one would expect an excess of B-cell tumors among NHL cases.[76-78] An excess of B-cell neoplasms has, in fact, not been described in NHL cases from industrial or veteran cohorts to date.

Baseline Summary Results

Cancer received major emphasis during the Baseline Air Force Health Study (AFHS) in 1982. The malignancy assessment used data from both the in-home questionnaire and the review-of-systems questionnaire obtained during the physical examination as well as data from the examination itself. All subjective data were verified by medical record reviews. In addition, tabulation of mortality count data from the Baseline Mortality Report[79] was used in conjunction with cancer morbidity information. The overall results did not show a significant difference in systemic cancer between the two groups but did show significantly more skin cancer (p=0.03) in the Ranch Hands.

Of 50 reported systemic cancers from the Ranch Hand and Comparison groups, 28 (14 in each group) were verified by medical records and pathology reports. A visual inspection of anatomic sites showed a slight excess of genitourinary cancer and oropharyngeal cancer but a relative deficit of digestive system neoplasms in the Ranch Hands. A combined morbidity-mortality assessment derived from the initial 1:1 match (Ranch Hand to the Original Comparison member) disclosed similar distributions. One case of STS and one case of Hodgkin's Disease were confirmed, both in the Comparison group. Exposure analyses for industrial chemicals and x rays were negative, as were most of the herbicide exposure analyses in the Ranch Hand group. All of the exposure analyses were based upon very small numbers, and interactions were noted in several strata.

Questionnaire data verified by medical record reviews revealed significantly more skin cancer in the Ranch Hands (odds ratio 2.35). Basal cell carcinoma accounted for 83.9 percent of the reported skin cancers in both groups and was concentrated anatomically on the face, head, and neck. The few melanoma and squamous cell cancers were evenly distributed between the Ranch Hand and Comparison groups. All skin cancers occurred in nonblacks. Adjustments for occupational exposures (e.g., asbestos, degreasing chemicals) did not alter the increased rate of skin cancer in the Ranch Hand group.

Skin cancer in both groups was associated with exposure to industrial chemicals (p=0.03). Herbicide exposure analyses in the Ranch Hand group were essentially negative, although confounding was noted in many of the analyses. Outdoor occupations subsequent to military service as a covariate did not account for the significant skin cancer association.

1985 Followup Study Summary Results

The Baseline and 1985 followup data were combined for the assessment of lifetime incidence of cancer; occurrences of cancer prior to Vietnam were excluded.

For the unadjusted analyses (Blacks and nonblacks included), Ranch Hands had a significantly greater frequency of verified skin neoplasms (malignant, benign, uncertain behavior, and unspecified nature) than the Comparisons. Inclusion of the suspected skin neoplasms with these verified skin neoplasms resulted in the Ranch Hands having a marginally significantly higher frequency than the Comparisons. There were no significant unadjusted group differences among nonblack participants for basal cell carcinoma, squamous cell carcinoma, melanoma, or all malignant skin neoplasms. For verified sun exposure-related malignant skin neoplams, Ranch Hands had a marginally significantly greater frequency than the Comparisons. The groups did not differ for verified and suspected sun exposure-related malignant skin neoplasms.

The adjusted group contrast in incidence rates of the sun exposure-related skin cancers was also significant (p=0.030), the majority of which were basal cell carcinoma. Inclusion of the suspected conditions resulted in a nonsignificant group contrast. The unadjusted group contrasts of the incidence rates of all systemic cancers combined were not significant, both for verified and verified and supected conditions. There was one new occurrence of an STS (Ranch Hand) and one suspected cancer of the lymphatic

10-5

system (Ranch Hand), in addition to the one previously reported STS and one
Hodgkin's Disease in the Comparison group. There were no cases of NHL in
either group at the time of the 1985 report.

Adjusted analysis of all lifetime malignant systemic neoplasms as a
group, however, revealed a group-by-occupation interaction, due to a
significantly higher rate for Ranch Hand enlisted flyers as contrasted to
Comparisons. The same result was found for verified and suspected systemic
cancers. These findings were in error due to miscoded records. Reanalysis of
corrected data revealed no significant group difference (odds ratio = 1.1).

At Baseline, a significantly higher rate of basal cell carcinoma was
found for Ranch Hands when contrasted with Original Comparisons. When the
Baseline data were combined with the 1985 interval data, adjusted analysis,
but not the unadjusted analysis, revealed a significantly higher rate of basal
cell carcinoma among the Ranch Hands than among all Comparisons. The relative
risk of basal cell carcinoma appeared to be declining over time.

Relative risks of basal cell carcinoma and systemic cancer were found to
be consistently larger than 1. Most of the skin cancers were basal cell
carcinomas, upon which most of the skin cancer analysis focused; thus,
relative risks for sun exposure-related malignant skin neoplasms and all
malignant skin cancers as a group were very similar to those for basal cell
carcinoma. The number of occurrences of systemic cancer was small, in part
because the cohort was relatively young, and although the relative risks were
sometimes greater than 1, the difference between groups was not significant.

Parameters of the 1987 Malignancy Assessment

Dependent Variables

The 1987 malignancy assessment was based on lifetime incidence of
neoplasms exclusive of the few neoplasm occurrences before duty in Southeast
Asia (SEA). Information on the occurrence of neoplasms was captured in the
health questionnaires and the physical examinations at Baseline and both
followups. The questionnaire and physical examination information on
neoplasms collected in the Baseline, 1985 followup, and 1987 followup studies
was combined to form a lifetime incidence of neoplasms for each participant.
In this chapter, lifetime is used to refer to lifetime exclusive of time
before duty in SEA.

Neoplasm refers to any new growth that may or may not be malignant.
Malignant neoplasms are those neoplasms that are capable of invasion and
metastasis. Malignant and benign neoplasms, carcinomas in situ, and neoplasms
of uncertain behavior or unspecified nature were studied. Both skin and
systemic neoplasms were studied. Systemic neoplasm is used to denote a
nonskin neoplasm.

There were slight differences among the Baseline, 1985 followup, and 1987
followup cohorts. Unless otherwise noted, the 1987 assessment was based on
the participants of the 1987 followup. All of the analyses were based on the

number of participants with one or more neoplasms, and not on the total number of neoplasms.

Questionnaire and Physical Examination Data

During the 1987 health interview, each study participant was asked a series of questions on the occurrence of cancer since the date of his last health interview. Participants who were new to the AFHS also completed the Baseline health questionnaire. The self-reported occurrences were verified by medical record review. The verification status of each self-reported neoplasm was classified as one of the following: (1) verified (supported by medical record), (2) nonverifiable (not supported by medical record), or (3) pending (medical record not yet provided). The reported neoplasms for which the verification status is pending are referred to as suspected neoplasms. Other than the analysis of nonverifiable neoplastic conditions, only data on verified and suspected neoplasms were used in the malignancy assessment.

Some possible neoplastic conditions were discovered by the physicians at the physical examination. No invasive procedures were used to detect systemic neoplasms. Punch biopsies were sought for all suspected malignant skin lesions. Contingent upon participant authorization, suspicious skin lesions were biopsied, and the pathology was determined. However, for some suspicious skin lesions and all suspected systemic neoplasms, the verification process has not been completed. Both the verified and suspected (verification not completed) neoplasms from the physical examination were used in the analysis. This is deemed necessary in order to best describe the complete neoplasm findings, recognizing that confirmation of all suspected cases was difficult.

The verified questionnaire data and the verified physical examination data were combined and are denoted as verified. The verified neoplasms plus the suspected neoplasms identified during the physical examination or those reported pending final verification by medical record, are referred to as verified and suspected neoplasms.

Skin Neoplasms

The analysis of skin neoplasms for the 1987 malignancy assessment was divided into the five sets described below. Each set was analyzed twice. The first analysis was limited to verified skin neoplasms only. For the second analysis, the skin neoplasms were expanded to include the verified neoplasms as well as the suspected neoplasms.

Set 1 consisted of analyses of skin neoplasms by behavior. Four behavior types were examined: (1) malignant, (2) benign, (3) uncertain behavior or unspecified nature, and (4) all (all skin neoplasms combined).

Set 2 consisted of analyses of malignant skin neoplasms by cell type. Four types were analyzed: (1) basal cell carcinoma, (2) squamous cell carcinoma, (3) melanoma, and (4) sun exposure-related malignant skin neoplasms. Sun exposure-related malignant skin neoplasms included basal cell carcinoma, squamous cell carcinoma, melanoma, and malignant epithelial neoplasms not otherwise specified (NOS).

Set 3 consisted of analyses of basal cell carcinoma, melanoma, and sun exposure-related malignant skin neoplasms by location. Five locations were used: (1) ear, face, head, and neck; (2) trunk; (3) upper extremities; (4) lower extremities; and (5) other sites including sites NOS.

Set 4 consisted of analyses on basal cell carcinoma and sun exposure-related malignant skin neoplasms. For both groups of neoplasms, Ranch Hands and Comparisons were contrasted on the number of participants with neoplasms on the ear, face, head, and neck, versus the number of participants with no neoplasms. These analyses were repeated using all other sites combined except ear, face, head, and neck. These analyses were stratified by occupation.

Set 5 consisted of five conditional analyses: (1) skin neoplasm conditioned on the occurrence of any neoplasm; (2) malignant skin neoplasm conditioned on the occurrence of any skin neoplasm; (3) basal cell carcinoma conditioned on malignant skin neoplasm; (4) basal cell carcinoma on the ear, face, head, neck, or upper extremities conditioned on the occurrence of basal cell carcinoma; and (5) sun exposure-related malignant skin neoplasm on the ear, face, head, neck, or upper extremities conditioned on the occurrence of sun exposure-related malignant skin neoplasm.

In addition, analyses of participants with multiple basal cell carcinomas versus no basal cell carcinomas were conducted; once limited to verified data only and repeated for verified and suspected malignancies.

Since Blacks have a lower susceptibility to sun-induced skin cancer, the analysis of skin neoplasms was limited to nonblacks. No participants were excluded for medical reasons from the analyses of these variables.

Systemic Neoplasms

The systemic neoplasms were analyzed by behavior and body site. As with skin neoplasms, each analysis was conducted twice, once limited to verified data and expanded to encompass the suspected neoplasms. The analysis of the systemic neoplasms was divided into the two sets described below.

Set 1 consisted of analyses of systemic neoplasms by behavior. Four behavior types were examined: (1) malignant, (2) benign, (3) uncertain behavior and unspecified nature, and (4) all (all systemic neoplasms combined).

Set 2 consisted of analyses of malignant systemic neoplasms by site or certain types of malignant systemic neoplasms. The site or type of neoplasm classifications were as follows: (1) oral cavity, pharynx, and larynx; (2) thyroid gland; (3) bronchus and lung; (4) colon; (5) kidney and bladder; (6) prostate; (7) testicles; (8) Hodgkin's Disease; (9) ill-defined sites; (10) thymus and mediastinum; (11) head, face, and neck; (12) brain; (13) other malignant neoplasms of lymphoid and histiocytic tissue; (14) leukemia; (15) carcinoma in situ of the penis; and (16) carcinoma in situ of other specified sites.

In addition, analyses were conducted on malignant systemic neoplasms conditioned on the occurrence of any systemic neoplasm.

No participants were excluded for medical reasons from the analysis of these variables.

Skin and Systemic Neoplasms

All neoplasms (skin and systemic combined) were analyzed, once limited to verified neoplasms and also based on verified and suspected neoplasms. In addition, nonverifiable neoplasms were analyzed to examine overreporting.

There were no medical exclusions in the analysis of these variables.

Morbidity and Mortality Data

This portion of the analysis addressed the mortality and malignant neoplasms of fully compliant Baseline participants. For this portion, mortality and morbidity information was combined. Mortality data through the end of 1987 were used. This analysis addressed the question of whether mortality from and incidence of malignant neoplasms, among individuals not participating in the 1987 followup, affected the preceding analyses of incidence of malignant neoplasms among 1987 followup participants.

Frequencies of fully compliant Baseline participants by status (living or deceased) at the 1987 followup examination by group were tabulated. An analysis of the participants who did not return to the 1987 followup with incident or fatal neoplasms was conducted. In addition, the pattern of neoplasm incidence at the Baseline, 1985 followup, and 1987 followup was summarized, based on the fully compliant Baseline participants who also attended the 1985 and 1987 followup examinations.

No participants were excluded for medical reasons from these analyses.

Covariates

The emphasis on cancer was increased during the 1985 followup. In particular, the interval health questionnaire was modified to collect information on each geographic location in which a participant lived for more than 12 months. Because ultraviolet light exposure has been acknowledged as the primary cause of basal cell carcinoma, this information was used to compute a cumulative sun-exposure measure based on residential history. In addition, detailed information on skin tannability; eye, skin, and hair color; parental ethnicity; and lifetime smoking history was obtained. This information was obtained for participants in the 1987 followup who did not attend the 1985 followup.

In the 1987 followup, the questionnaire was expanded to capture a detailed history of alcohol consumption. Baseline questions on exposure to selected carcinogens were repeated to collect interval data. Interval smoking patterns were also captured.

The effects of 34 covariates were examined in the skin malignancy assessment in pairwise associations with basal cell carcinoma and sun exposure-related malignant skin neoplasms. Two of the matching variables, age and occupation, were used as candidate covariates in the adjusted analyses of these dependent variables. Race was not used as a covariate because analyses of skin neoplasms were limited to nonblacks. Other covariates considered for the adjusted analyses were lifetime cigarette smoking history, lifetime alcohol history, ethnic background, skin color, hair color, eye color, reactions of skin to sun exposure, a composite sun-reaction index, average lifetime residential latitude, exposure to carcinogens and groups of carcinogens, and composite carcinogen exposure. Based on an evaluation of the pairwise associations between the individual candidate covariates and the dependent variables, and a statistical modeling strategy (both of which are discussed later in this chapter), the set of 34 candidate covariates was reduced. The reduced subset of covariates that were used for the adjusted analyses of skin neoplasms consisted of occupation, age, reaction of skin after at least 2 hours sun exposure and after repeated sun exposure, ethnic background, and average lifetime residential latitude.

Definitions and categories of selected covariates are provided below:

● Ethnic Background: (A) English, Welsh, Scottish, or Irish; (B) Scandinavian, German, Polish, Russian, other Slavic, Jewish, or French; (C) Spanish, Italian, or Greek; and (D) Mexican, American Indian, or Asian; (E) African. From information collected at the 1985 followup, participants were assigned to one of these five categories based on their responses to questions on racial or ethnic group. These categories are approximate groupings in terms of susceptibility to sun-induced skin damage. Information from the 1987 followup was used for participants who did not attend the 1985 followup.

● Skin Color: dark, medium, pale, dark peach, and pale peach. Skin color was coded by the dermatologist at the 1985 physical examination. Skin color groupings from dark brown through pale peach were determined by comparing standardized flesh-colored squares[80] against the skin of the inside upper arm. Information from the 1987 followup was used for participants who did not attend the 1985 followup.

● Hair Color: black, dark brown, light brown, blonde, and red. Hair color was determined at the 1985 physical examination by comparing the hair at the back of the neck with 17 numbered standardized hair samples[81] and selecting the most closely matching hair sample. Information from the 1987 followup was used for participants who did not attend the 1985 followup.

● Eye Color: brown, hazel, green, gray, and blue. Eye color was determined during the dermatologic assessment of the 1985 physical examination. Information from the 1987 followup was used for participants who did not attend the 1985 followup.

● Reaction of Skin to Sun Exposure consisted of two reactions: (1) Assuming several preceding episodes of sun exposure, 2 or more hours of sun exposure will result in the following skin reaction: burns painfully, burns, becomes red, and no reaction. (2) Assuming repeated episodes of sun exposure, skin reaction is: freckles with no tan, tans mildly, tans moderately, and tans deep brown.

- Composite Sun-Reaction Index: A composite variable was based on the two reactions of skin to sun exposure variables and was defined as follows: (1) High: burns painfully from 2 or more hours of sun exposure (assuming several preceding episodes of sun exposure) and/or freckles with no tan (assuming repeated episodes of sun exposure); (2) Medium: burns (assuming several preceding episodes of sun exposure) and/or tans mildly (assuming repeated episodes of sun exposure); (3) Low: all other reactions.

- Average Lifetime Residential Latitude: average latitude less than 37 degrees and average greater than or equal to 37 degrees. A lifetime residential history was gathered from participants through the 1985 health interval questionnaires. The residential history, relative to the equator, was used as a surrogate measure of sun exposure. Participants were asked to list all residences chronologically, citing both the city (or military installation) and the years of residence at each location since birth. Residences of less than 1 year were not sought because of the frequent short-term military travels of these cohorts. Using standard geographic atlases, the latitude (in degrees and minutes) of each residence was recorded. The average lifetime residential latitude of each participant was calculated by dividing the total degree-years (i.e., the sum of latitude [degrees] times number of years lived there) from all residences by the total number of residential years listed. This information was compiled for residential histories up to the time of the 1985 followup examination.

- Exposure to Carcinogens or Groups of Carcinogens:

  Set 1: asbestos, ionizing radiation, industrial chemicals, herbicides, insecticides, and degreasing chemicals (yes/no for each). Exposure information for these items was obtained from questionnaire responses from the Baseline, 1985 followup, and 1987 followup studies and combined to create cumulative history variables.

  Set 2: anthracene, arsenic, benzene, benzidene, chromates, coal tar, creosote, aminodiphenyl, chloromethyl ether, mustard gas, naphthylamine, cutting oils, trichloroethylene, ultraviolet light (not sun), and vinyl chloride (yes/no for each). Self-reported exposure information on these 15 individual carcinogens was obtained at the 1987 followup for each participant.

  Composite Carcinogen Exposure: yes, if exposure to any carcinogen in set 2; otherwise, no.

Because of the significant confounding effect of the average lifetime residential latitude variable, an analysis of the inaccuracy of residential reporting was conducted for this covariate to evaluate reporting bias by group.

The candidate covariates for the systemic malignancy assessment were the same as those for the skin malignancy assessment with the following exceptions:

- Race was added as a candidate covariate.

- Covariates specific to skin were deleted: ethnic background, skin color, hair color, eye color, reaction of skin to sun exposure, sun-reaction index, and average lifetime residential latitude.

Relation to Baseline and 1985 Followup Studies

Most variables analyzed for the 1987 followup were analyzed in the 1985 followup. Basal cell carcinoma has replaced a similar analysis involving nonmelanoma malignant neoplasms by location and occupation (see Set 4 under Skin Neoplasm section). In general, the same variables were analyzed in the Baseline study, although less covariate information had been captured at that time.

Statistical Methods

The basic statistical analysis methods to be used in the malignancy assessment are described in Chapter 7.

Table 10-1 summarizes the statistical analyses performed for the 1987 malignancy assessment. The first part of the table identifies the dependent variables and the statistical methods. This information is presented in four sections: skin neoplasms, systemic neoplasms, skin and systemic neoplasms, and morbidity and mortality data. Data source, data form, cutpoints, and candidate covariates for dependent variables are summarized at the end of the table. The second part of the table lists the candidate covariates. Abbreviations used in the body of the table are defined in footnotes. For the skin and systemic neoplasm analyses, some covariate information was missing. The number of participants with missing data is presented in Table 10-2 by group.

RESULTS

Ranch Hand and Comparison Group Contrast

Ranch Hand and Comparison group analyses are presented for the following three sets of neoplasms: skin neoplasms, systemic neoplasms, and the combined set of skin and systemic neoplasms. For the skin and systemic neoplasm sets, the results of unadjusted analyses are presented first, followed by a discussion of covariate associations with the dependent variables, and then the results from adjusted analyses are presented. For the combined set of skin and systemic neoplasms, only unadjusted analyses were performed.

TABLE 10-1.

Statistical Analysis for the Malignancy Assessment

Dependent Variables

Category	Location/ Site	Statistical Analyses
Skin Neoplasms		
Behavior		
Malignant	All	UC:FT
Benign	All	UC:FT
Uncertain Behavior or Unspecified Nature	All	UC:FT
All	All	UC:FT
Cell Type		
Basal Cell Carcinoma	All	UC:FT AC:LR CA:CS,FT UE:CS,FT AE:LR
Squamous Cell Carcinoma	All	UC:FT
Melanoma	All	UC:FT
Sun Exposure-Related Malignant	All	UC:FT AC:LR CA:CS,FT UE:CS,FT AE:LR
Cell Type and Location/Site		
Basal Cell Carcinoma	Ear, Face, Head, and Neck Trunk Upper Extremities Lower Extremities Other Sites and NOS	UC:FT

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Dependent Variables

Category	Location/Site	Statistical Analyses
Skin Neoplasms		
Melanoma	Ear, Face, Head, and Neck Trunk Upper Extremities Lower Extremities Other Sites and NOS	UC:FT
Sun Exposure-Related Malignant	Ear, Face, Head, and Neck Trunk Upper Extremities Lower Extremities Other Sites and NOS	UC:FT
Cell Type and Location/Site by Occupation		
Basal Cell Carcinoma	Ear, Face, Head, and Neck All Other Sites and NOS None	UC:CS,FT
Sun Exposure-Related Malignant	Ear, Face, Head, and Neck All Other Sites and NOS None	UC:CS,FT
Conditional Analyses		
Skin Neoplasm Conditioned on Neoplasm	All	UC:FT
Malignant Skin Neoplasm Conditioned on Skin Neoplasm	All	UC:FT
Basal Cell Carcinoma Conditioned on Malignant Skin Neoplasm	All	UC:FT
Basal Cell Carcinoma Conditioned on Basal Cell Carcinoma	Ear, Face, Head, Neck, or Upper Extremities	UC:FT

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Dependent Variables

Category	Location/ Site	Statistical Analyses
Skin Neoplasms		
Sun Exposure-Related Malignant Conditioned on Sun Exposure-Related Malignant	Ear, Face, Head, Neck, or Upper Extremities	UC:FT
<u>Multiple Basal Cell Carcinoma</u>	All	UC:CS,FT
Systemic Neoplasms		
<u>Behavior</u>		
Malignant	All	UC:FT AC:LR CA:CS,FT UE:CS,FT AE:LR
Benign	All	UC:FT
Uncertain Behavior or Unspecified Nature	All	UC:FT
All	All	UC:FT
<u>Location/Site or Type</u>		
Malignant	Oral Cavity, Pharynx and Larynx	UC:FT
Malignant	Thyroid Gland	UC:FT
Malignant	Bronchus and Lung	UC:FT
Malignant	Colon and Rectum	UC:FT
Malignant	Kidney and Bladder	UC:FT
Malignant	Prostate	UC:FT
Malignant	Testicles	UC:FT

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Dependent Variables

Category	Location/ Site	Statistical Analyses
Systemic Neoplasms		
Hodgkin's Disease	--	UC:FT
Malignant	Ill-Defined Sites	UC:FT
Malignant	Thymus and Mediastinum	UC:FT
Malignant	Head, Face, and Neck	UC:FT
Malignant	Brain	UC:FT
Malignant	Other Malignant Neoplasms of Lymphoid and Histio-cytic Tissue	UC:FT
Leukemia	--	UC:FT
Malignant	Carcinoma In Situ of Penis	UC:FT
Malignant	Carcinoma In Situ of Other Specified Sites	UC:FT
Conditional Analysis		
Malignant Conditioned on Systemic	All	UC:FT
Skin and Systemic Neoplasms		
All	All	UC:FT
Nonverifiable	All	UC:FT
Morbidity and Mortality Data		
Malignant (Did Not Participate in 1987 Followup)	All	UC:FT
Neoplasm Incidence Pattern	All	UC:FS

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Covariates

Variable (Abbreviation)	Data Source	Data Form	Cutpoints
Age (AGE)	MIL	D/C	Born >1942 Born 1923-1941 Born <1922
Race (RACE)	MIL	D	Nonblack Black
Occupation (OCC)	MIL	D	Officer Enlisted Flyer Enlisted Groundcrew
Lifetime Cigarette Smoking History (PACKYR) (pack-years)	Q-SR	D/C	0 >0-10 >10
Lifetime Alcohol History (DRKYR) (drink-years)	Q-SR	D/C	0 >0-40 >40
Average Lifetime Residential Latitude (LAT)	Q-SR (1985)	D	Latitude <37° Latitude >37°
Asbestos Exposure (ASB)	Q-SR	D	Yes No
Ionizing Radiation Exposure (RAD)	Q-SR	D	Yes No
Industrial Chemical Exposure (IC)	Q-SR	D	Yes No
Herbicide Exposure (HERB)	Q-SR	D	Yes No
Insecticide Exposure (INS)	Q-SR	D	Yes No
Degreasing Chemical Exposure (DC)	Q-SR	D	Yes No
Anthracene Exposure (ANTH)	Q-SR	D	Yes No

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Covariates

Variable (Abbreviation)	Data Source	Data Form	Cutpoints
Arsenic Exposure (ARS)	Q-SR	D	Yes No
Benzene Exposure (BENZ)	Q-SR	D	Yes No
Benzidene Exposure (BENZID)	Q-SR	D	Yes No
Chromate Exposure (CHROM)	Q-SR	D	Yes No
Coal Tar Exposure (COALTAR)	Q-SR	D	Yes No
Creosote Exposure (CREOS)	Q-SR	D	Yes No
Aminodiphenyl Exposure (AMDIPHEN)	Q-SR	D	Yes No
Chloromethyl Ether Exposure (CHLMETETH)	Q-SR	D	Yes No
Mustard Gas Exposure (MUSTGAS)	Q-SR	D	Yes No
Naphthylamine Exposure (NAPTHYL)	Q-SR	D	Yes No
Cutting Oil Exposure (CUTOIL)	Q-SR	D	Yes No
Trichloroethylene Exposure (TRICHLETH)	Q-SR	D	Yes No
Ultraviolet Light (Not Sun) Exposure (ULTLIGHT)	Q-SR	D	Yes No
Vinyl Chloride Exposure (VINCHL)	Q-SR	D	Yes No

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Covariates

Variable (Abbreviation)	Data Source	Data Form	Cutpoints
Composite Carcinogen Exposure (CARCIN)	Q-SR	D	Yes No
Ethnic Background (ETHBACK)	Q-SR (1985)	D	A: English, Welsh, Scottish, or Irish B: Scandinavian, German, Polish, Russian, other Slavic, Jewish, or French C: Spanish, Italian, or Greek D: Mexican, American Indian, or Asian E: African
Skin Color (SKIN)	PE (1985)	D	Dark Medium Pale Dark Peach Pale Peach
Hair Color (HAIR)	PE (1985)	D	Black Dark Brown Light Brown Blonde Red
Eye Color (EYE)	PE (1985)	D	Brown Hazel Green Gray Blue
Reaction of Skin to Sun After at Least 2 Hours of Sun Exposure (assuming several preceding episodes) (SUN2HR)	Q-SR	D	Burns Painfully Burns Becomes Red No Reaction
Reaction of Skin to Sun After Repeated Exposure (SUNREPEAT)	Q-SR	D	Freckles with No Tan Tans Mildly Tans Moderately Tans Deep Brown

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Covariates

Variable (Abbreviation)	Data Source	Data Form	Cutpoints
Composite Sun-Reaction Index (SUNREAC)	Q-SR	D	High: Burns Painfully (for SUN2HR) or Freckles With No Tan (for SUNREPEAT) Medium: Burns (for SUN2HR) or Tans Mildly (for SUNREPEAT) Low: All Other Reactions

Dependent Variables:

Data Source: All AFHS questionnaires and physical examinations

Data Form: Discrete

Cutpoints: Yes/No

Candidate Covariates for Skin Neoplasms: all covariates listed above except race

Candidate Covariates for Systemic Neoplasms: all covariates listed above except ethnic background, skin color, hair color, eye color, reaction of skin to sun exposure, composite sun-reaction index, and average lifetime residential latitude

Analyses: All analyses were conducted twice--verified only, and verified and suspected

Abbreviations:

Data Source: MIL--Air Force military records
                   PE (1985)--1985 SCRF physical examination: updated
                     with 1987 SCRF information for new/rejoining
                     participants
                   Q-SR--1987 NORC questionnaire (self-reported)
                   Q-SR (1985)--1985 NORC questionnaire (self-reported)

Data Form: D--Discrete analysis only
                   D/C--Appropriate form for analysis (either discrete
                     or continuous)

TABLE 10-1. (continued)

Statistical Analysis for the Malignancy Assessment

Abbreviations (continued):

Statistical Analyses: UC--Unadjusted core analyses
AC--Adjusted core analyses
CA--Dependent variable-covariate associations
UE--Unadjusted exposure index analyses
AE--Adjusted exposure index analyses

Statistical Methods: CS--Chi-square contingency table test
FT--Fisher's exact test
LR--Logistic regression analysis
FS--Frequency summary

Other: NOS--Not otherwise specified

TABLE 10-2.

Number of Participants With Missing Data for the Malignancy Assessment by Group

Variable	Analysis Use	Group Ranch Hand	Group Comparison	Total
Lifetime Alcohol History	COV	10	3	13
Average Lifetime Residential Latitude*	COV	2	6	8
Anthracene Exposure	COV	1	2	3
Arsenic Exposure	COV	1	2	3
Benzene Exposure	COV	0	1	1
Benzidene Exposure	COV	0	3	3
Chromate Exposure	COV	3	2	5
Coal Tar Exposure	COV	0	1	1
Creosote Exposure	COV	0	1	1
Aminodiphenyl Exposure	COV	0	3	3
Chloromethyl Ether Exposure	COV	2	1	3
Mustard Gas Exposure	COV	0	1	1
Naphthylamine Exposure	COV	1	2	3
Cutting Oil Exposure	COV	0	1	1
Trichloroethylene Exposure	COV	5	2	7
Ultraviolet Light (Not Sun) Exposure	COV	0	2	2
Vinyl Chloride Exposure	COV	1	2	3
Composite Carcinogen Exposure	COV	13	11	24
Ethnic Background*	COV	24	28	52

TABLE 10-2. (continued)

**Number of Participants With Missing Data for the
Malignancy Assessment by Group**

Variable	Analysis Use	Group Ranch Hand	Comparison	Total
Skin Color*	COV	1	0	1
Hair Color*	COV	0	1	1
Eye Color*	COV	1	2	3
Reaction of Skin to Sun After at Least 2 Hours of Sun Exposure (assuming several preceding episodes)	COV	0	1	1
Reaction of Skin to Sun After Repeated Exposure*	COV	0	1	1
Composite Sun Reaction Index*	COV	0	2	2

Abbreviations: COV--Covariate

*Nonblacks only.

Skin Neoplasms

Ranch Hands and Comparisons were compared on their relative frequencies of skin neoplasms for the following six groups of analyses: behavior, cell type, cell type and location/site, selected cell type and location/site by occupation, selected neoplasms conditioned on the presence of a specified neoplasm, and the occurrence of multiple basal cell carcinomas. For the assessment of cell type, covariate associations and the adjusted group analyses were performed for basal cell carcinoma and sun exposure-related malignant skin neoplasms.

Behavior

The unadjusted skin neoplasm analyses were based on 938 nonblack Ranch Hands and 1,219 nonblack Comparisons. Table 10-3 summarizes the Ranch Hand and Comparison frequency distributions for each of the following: malignant skin neoplasms, benign skin neoplasms, skin neoplasms of uncertain behavior or unspecified nature, and all skin neoplasms. For each of these neoplasms, unadjusted analyses were performed for verified neoplasms and for the verified and suspected neoplasms combined.

The Ranch Hands and Comparisons differed significantly (p=0.047) on the relative frequency of verified malignant skin neoplasms. The estimated relative risk for Ranch Hands versus Comparisons was 1.38 (95% C.I.: [1.02,1.88]). Among the Ranch Hands, 9.7 percent had a verified malignant skin neoplasm, contrasted with 7.2 percent for the Comparisons. For verified and suspected malignant skin neoplasms combined, the group difference was not significant (p=0.101).

For verified benign neoplasms, the Ranch Hand and Comparison groups did not differ significantly (p=0.292). There were no suspected benign skin neoplasms for either group.

For the verified skin neoplasms of uncertain behavior or unspecified nature, the Ranch Hand and Comparison groups did not differ significantly (p=0.442). For the verified and suspected skin neoplasms of uncertain behavior or unspecified nature, the Ranch Hand and Comparison contrast also was not significant (p=0.758).

For all verified skin neoplasms (malignant, benign, or uncertain), there was a significant difference between the Ranch Hand and Comparison groups (p=0.012). For this aggregation of skin neoplasms, the estimated relative risk for Ranch Hands versus Comparisons was 1.37 (95% C.I.: [1.08,1.74]). The percentage of Ranch Hands with a verified skin neoplasm was 16.7 percent versus 12.8 percent for the Comparisons. For all verified and suspected skin neoplasms, the Ranch Hands and Comparisons also differed significantly (p=0.029) with an associated estimated relative risk of 1.31 (95% C.I.: [1.04,1.66]). The Ranch Hand and Comparison relative frequencies for the verified and suspected set of skin neoplasms were 16.8 percent and 13.4 percent, respectively.

TABLE 10-3.

Unadjusted Analysis for Skin Neoplasms by Behavior, Status, and Group
(Nonblacks Only)

Behavior (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Malignant (Verified)	n	938	1,219		
	Number/%				
	Yes	91 9.7%	88 7.2%	1.38 (1.02,1.88)	0.047
	No	847 90.3%	1,131 92.8%		
Malignant (Verified and Suspected)	n	938	1,219		
	Number/%				
	Yes	92 9.8%	94 7.7%	1.30 (0.96,1.76)	0.101
	No	846 90.2%	1,125 92.3%		
Benign (Verified*)	n	938	1,219		
	Number/%				
	Yes	66 7.0%	71 5.8%	1.22 (0.87,1.73)	0.292
	No	872 93.0%	1,148 94.2%		
Uncertain Behavior or Unspecified Nature (Verified)	n	938	1,219		
	Number/%				
	Yes	3 0.3%	1 0.1%	3.91 (0.41,37.63)	0.442
	No	935 99.7%	1,218 99.9%		

TABLE 10-3. (continued)

Unadjusted Analysis for Skin Neoplasms by Behavior, Status, and Group
(Nonblacks Only)

Behavior (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Uncertain Behavior or	n Number/%	938	1,219		
Unspecified	Yes	3 0.3%	2 0.2%	1.95 (0.33,11.71)	0.758
Nature (Verified and Suspected)	No	935 99.7%	1,217 99.8%		
All (Verified)	n Number/%	938	1,219		
	Yes	157 16.7%	156 12.8%	1.37 (1.08,1.74)	0.012
	No	781 83.3%	1,063 87.2%		
All (Verified and Suspected)	n Number/%	938	1,219		
	Yes	158 16.8%	163 13.4%	1.31 (1.04,1.66)	0.029
	No	780 83.2%	1,056 86.6%		

*No suspected neoplasms; therefore, verified and suspected same as verified.

Cell Type

The occurrence of malignant skin neoplasms in the Ranch Hand and Comparison groups was also analyzed with respect to the individual neoplasm being classified as basal cell, squamous cell, melanoma, or sun exposure-related (i.e., neoplasms classified as basal cell carcinoma, squamous cell carcinoma, melanoma, and malignant epithelial neoplasm NOS). Table 10-4 presents unadjusted results of comparing the Ranch Hand and Comparison groups for each cell type, for both the verified and the verified and suspected malignant skin neoplasms.

For verified basal cell carcinoma, the Ranch Hand and Comparison contrast was borderline significant (p=0.076) with an estimated relative risk of 1.36 (95% C.I.: [0.98,1.89]). The Ranch Hands had a higher relative frequency of verified basal cell carcinoma than the Comparisons (8.3% vs. 6.2%). When suspected basal cell carcinomas were included with the verified basal cell carcinoma, the Ranch Hand and Comparison groups were not significantly different (p=0.140).

The unadjusted analysis of verified squamous cell carcinoma for the Ranch Hand and Comparison groups was not significant (p=0.656). There were no suspected squamous cell carcinomas.

For verified melanoma, the Ranch Hand and Comparison groups did not differ (p=0.976). There were no suspected melanomas.

The contrast of Ranch Hand and Comparison relative frequencies of verified sun exposure-related malignant skin neoplasms was significant (p=0.042) with an estimated relative risk of 1.40 (95% C.I.: [1.02,1.91]). For Ranch Hands, the frequency of verified sun exposure-related malignant skin neoplasms was 9.4 percent versus 6.9 percent for the Comparisons. For the verified and suspected sun exposure-related malignant skin neoplasms, the relative frequency of 9.5 percent for the Ranch Hand group was marginally significant (p=0.081) when compared to the relative frequency of 7.3 percent for the Comparison group. This Ranch Hand and Comparison contrast for verified and suspected sun exposure-related malignant skin neoplasms had an estimated relative risk of 1.33 (95% C.I.: [0.98,1.81]).

Cell Type and Location/Site

Table 10-5 summarizes the unadjusted analyses of the Ranch Hand and Comparison relative frequencies of verified basal cell carcinoma and verified and suspected basal cell carcinoma at the following locations/sites: ear, face, head, and neck; trunk; upper extremities; lower extremities; and other sites including sites NOS. For each location/site, the frequency of verified basal cell carcinoma among Ranch Hands was not significantly different from that of the Comparisons (ear, face, head, and neck: p=0.456; trunk: p=0.310; upper extremities: p=0.193; other sites: p=0.462). No verified basal cell carcinomas of the lower extremities were found for either the Ranch Hands or the Comparisons, and there were no suspected basal cell carcinomas of the upper or lower extremities for either group. No significant results were found when suspected basal cell carcinomas were included with the verified basal cell carcinomas (ear, face, head, and neck: p=0.554; trunk: p=0.384; other sites: p=0.720).

TABLE 10-4.

Unadjusted Analysis for Malignant Skin Neoplasms by Cell Type, Status, and Group
(Nonblacks Only)

Cell Type (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Basal Cell Carcinoma (Verified)	n	938	1,219		
	Number/%				
	Yes	78 8.3%	76 6.2%	1.36 (0.98,1.89)	0.076
	No	860 91.7%	1,143 93.8%		
Basal Cell Carcinoma (Verified and Suspected)	n	938	1,219		
	Number/%				
	Yes	79 8.4%	81 6.6%	1.29 (0.94,1.78)	0.140
	No	859 91.6%	1,138 93.4%		
Squamous Cell Carcinoma (Verified*)	n	938	1,219		
	Number/%				
	Yes	6 0.6%	5 0.4%	1.56 (0.48,5.14)	0.656
	No	932 99.4%	1,214 99.6%		
Melanoma (Verified*)	n	938	1,219		
	Number/%				
	Yes	4 0.4%	4 0.3%	1.30 (0.32,5.22)	0.976
	No	934 99.6%	1,215 99.7%		
Sun Exposure-Related (Verified)	n	938	1,219		
	Number/%				
	Yes	88 9.4%	84 6.9%	1.40 (1.02,1.91)	0.042
	No	850 90.6%	1,135 93.1%		

TABLE 10–4. (continued)

Unadjusted Analysis for Malignant Skin Neoplasms by Cell Type, Status, and Group
(Nonblacks Only)

Cell Type (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Sun Exposure- Related	n Number/%	938	1,219		
(Verified and	Yes	89 9.5%	89 7.3%	1.33 (0.98,1.81)	0.081
Suspected)	No	849 90.5%	1,130 92.7%		

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

TABLE 10-5.

Unadjusted Analysis for Basal Cell Carcinoma by Location/Site, Status, and Group
(Nonblacks Only)

Location/Site (Status)	Statistic	Ranch Hand		Comparison		Est. Relative Risk (95% C.I.)	p-Value
Ear, Face, Head, and Neck (Verified)	n	938		1,219			
	Number/%						
	Yes	53	5.7%	59	4.8%	1.18 (0.80,1.72)	0.456
	No	885	94.3%	1,160	95.2%		
Ear, Face, Head, and Neck (Verified and Suspected)	n	938		1,219			
	Number/%						
	Yes	54	5.8%	62	5.1%	1.14 (0.78,1.66)	0.554
	No	884	94.2%	1,157	94.9%		
Trunk (Verified)	n	938		1,219			
	Number/%						
	Yes	22	2.3%	20	1.6%	1.44 (0.78,2.65)	0.310
	No	916	97.7%	1,199	98.4%		
Trunk (Verified and Suspected)	n	938		1,219			
	Number/%						
	Yes	22	2.3%	21	1.7%	1.37 (0.75,2.51)	0.384
	No	916	97.7%	1,198	98.3%		
Upper Extremities (Verified*)	n	938		1,219			
	Number/%						
	Yes	9	1.0%	5	0.4%	2.35 (0.79,7.04)	0.193
	No	929	99.0%	1,214	99.6%		

TABLE 10-5. (continued)

Unadjusted Analysis for Basal Cell Carcinoma by Location/Site, Status, and Group
(Nonblacks Only)

Location/Site (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Lower Extremities (Verified*)	n Number/% Yes No	938 0 0.0% 938 100.0%	1,219 0 0.0% 1,219 100.0%	--ᵃ	--ᵃ
Other Sites (Verified)	n Number/% Yes No	938 4 0.4% 934 99.6%	1,219 2 0.2% 1,217 99.8%	2.61 (0.48,14.26)	0.462
Other Sites (Verified and Suspected)	n Number/% Yes No	938 4 0.4% 934 99.6%	1,219 3 0.2% 1,216 99.8%	1.74 (0.39,7.78)	0.720

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

--ᵃEstimated relative risk/confidence interval/p-value not given due to cells with zero frequency.

Table 10-6 presents the unadjusted analyses of the Ranch Hand and Comparison relative frequencies of verified melanoma by location/site. There were no suspected cases of melanoma; therefore, only unadjusted analyses for verified melanoma were performed. The Ranch Hand and Comparison groups did not differ with respect to the frequency of verified melanoma on the ear, face, head, and neck (p=0.870). No group difference was found for verified melanoma on the trunk (p=0.999). No verified melanomas on the upper extremities, lower extremities, or other sites were observed in either the Ranch Hand group or the Comparison group.

Table 10-7 summarizes the unadjusted group contrast analyses for each of the specified locations/sites of interest for verified, and verified and suspected, sun exposure-related malignant skin neoplasms. There was no significant group difference (p=0.260) for verified sun exposure-related malignant skin neoplasms on the ear, face, head, and neck, nor was there a significant group difference (p=0.330) at these sites when verified and .suspected sun exposure-related malignant skin neoplasms were combined. For sun exposure-related malignant skin neoplasms on the trunk, the Ranch Hands and Comparisons also did not differ significantly for the verified set (p=0.342) or the verified and suspected set (p=0.412). For upper extremity sites, the Ranch Hand group had a significantly higher frequency of verified sun exposure-related malignant skin neoplasms relative to the Comparisons (p=0.044). The estimated relative risk associated with this difference was 3.15 (95% C.I.: [1.11,8.96]), based on the Ranch Hand frequency of 1.3 percent versus the Comparison frequency of 0.4 percent. For the upper extremities, there were no suspected sun exposure-related malignant skin neoplasms. Neither group had a verified or suspected sun exposure-related malignant skin neoplasm on the lower extremities. For other sites, Ranch Hands and Comparisons did not differ on the frequency of sun exposure-related malignant skin neoplasms for either the verified set (p=0.462) or the verified and suspected set (p=0.720).

Basal Cell Carcinoma and Sun Exposure-Related Malignant Skin Neoplasms Occurring on the Ear, Face, Head, and Neck by Occupation

For each occupational stratum, Ranch Hands and Comparisons were compared on their relative frequencies of both basal cell carcinoma and sun exposure-related malignant skin neoplasms for the following three categories: malignant skin neoplasms of the ear, face, head, and neck; malignant skin neoplasms of all other sites; and no malignant skin neoplasms. Malignant skin neoplasms on the ear, face, head, or neck took precedence over other locations/sites (i.e., if a participant had a malignant skin neoplasm on the ear, face, head, or neck and also another site, he was assigned to the former classification). The analyses were performed using only verified malignant skin neoplasms and were also repeated aggregating the verified and suspected malignant skin neoplasms. Table 10-8 summarizes the results of these analyses.

For each occupation, no significant group differences were found for verified basal cell carcinoma (officers: p=0.107; enlisted flyers: p=0.130; enlisted groundcrew: p=0.857). Analyses of verified and suspected basal cell carcinoma also produced no significant overall group differences by occupation (officers: p=0.176; enlisted flyers: p=0.133; enlisted groundcrew: p=0.917).

TABLE 10-6.

Unadjusted Analysis for Melanoma by Location/Site, Status, and Group
(Nonblacks Only)

Location/Site (Status)	Statistic	Group Ranch Hand	Group Comparison	Est. Relative Risk (95% C.I.)	p-Value
Ear, Face, Head, and Neck (Verified*)	n Number/% Yes No	938 1 0.1% 937 99.9%	1,219 0 0.0% 1,219 100.0%	--[a]	0.870
Trunk (Verified*)	n Number/% Yes No	938 3 0.3% 935 99.7%	1,219 4 0.3% 1,215 99.7%	0.98 (0.22,4.37)	0.999
Upper Extremities (Verified*)	n Number/% Yes No	938 0 0.0% 938 100.0%	1,219 0 0.0% 1,219 100.0%	--[a]	--[a]
Lower Extremities (Verified*)	n Number/% Yes No	938 0 0.0% 938 100.0%	1,219 0 0.0% 1,219 100.0%	--[a]	--[a]

TABLE 10-6. (continued)

Unadjusted Analysis for Melanoma by Location/Site, Status, and Group
(Nonblacks Only)

Location/Site (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Other Sites (Verified*)	n	938	1,219		
	Number/%				
	Yes	0 0.0%	0 0.0%	--[a]	--[a]
	No	938 100.0%	1,219 100.0%		

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

--[a]Estimated relative risk/confidence interval/p-value not given due to cells with zero frequency.

TABLE 10-7.

Unadjusted Analysis for Sun Exposure-Related Malignant Skin Neoplasms by Location/Site, Status, and Group (Nonblacks Only)

Location/Site (Status)	Statistic	Group Ranch Hand		Group Comparison		Est. Relative Risk (95% C.I.)	p-Value
Ear, Face, Head, and Neck (Verified)	n	938		1,219			
	Number/%						
	Yes	60	6.4%	63	5.2%	1.25 (0.87,1.81)	0.260
	No	878	93.6%	1,156	94.8%		
Ear, Face, Head, and Neck (Verified and Suspected)	n	938		1,219			
	Number/%						
	Yes	61	6.5%	66	5.4%	1.22 (0.85,1.74)	0.330
	No	877	93.5%	1,153	94.6%		
Trunk (Verified)	n	938		1,219			
	Number/%						
	Yes	26	2.8%	25	2.1%	ь (0.78,2.37)	0.342
	No	912	97.2%	1,194	97.9%		
Trunk (Verified and Suspected)	n	938		1,219			
	Number/%						
	Yes	26	2.8%	26	2.1%	.ь1 (0.75,2.27)	0.412
	No	912	97.2%	1,193	97.9%		
Upper Extremities (Verified*)	n	938		1,219			
	Number/%						
	Yes	12	1.3%	5	0.4	3.15 (1.11,8.96)	0.044
	No	926	98.7%	1,214	99.		

TABLE 10-7. (continued)

**Unadjusted Analysis for Sun Exposure-Related Malignant Skin Neoplasms
by Location/Site, Status, and Group (Nonblacks Only)**

Location/Site (Status)	Statistic	Group Ranch Hand		Comparison		Est. Relative Risk (95% C.I.)	p-Value
Lower	n	938		1,219			
Extremities	Number/%						
(Verified*)	Yes	0	0.0%	0	0.0%	--ᵃ	--ᵃ
	No	938	100.0%	1,219	100.0%		
Other	n	938		1,219			
Sites	Number/%						
(Verified)	Yes	4	0.4%	2	0.2%	2.61 (0.48,14.26)	0.462
	No	934	99.6%	1,217	99.8%		
Other	n	938		1,219			
Sites	Number/%						
(Verified and	Yes	4	0.4%	3	0.2%	1.74 (0.39,7.78)	0.720
Suspected)	No	934	99.6%	1,216	99.8%		

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

--ᵃEstimated relative risk/confidence interval/p-value not given due to cells with zero frequency.

TABLE 10-8.

Unadjusted Analysis of Basal Cell Carcinoma and Sun Exposure-Related Malignant Neoplasms
on the Ear, Face, Head, and Neck or Other Sites by Occupation
(Nonblacks Only)

Cell Type (Status)	Occupation	Statistic	Group Ranch Hand		Comparison		Contrast	Est. Relative Risk (95% C.I.)	p-Value
Basal Cell Carcinoma (Verified)	Officer	n	372		488				
		Number/%							
		Ear, Face, Head, and Neck	30	8.1%	26	5.3%	Overall		0.107
		Other Sites	11	3.0%	8	1.6%	EFHN vs. None	1.58 (0.92,2.73)	0.128
		No Cancer	331	89.0%	454	93.0%	Other vs. None	1.89 (0.75,4.74)	0.256
	Enlisted Flyer	n	163		196				
		Number/%							
		Ear, Face, Head, and Neck	8	4.9%	12	6.1%	Overall		0.130
		Other Sites	7	4.3%	2	1.0%	EFHN vs. None	0.82 (0.33,2.06)	0.854
		No Cancer	148	90.8%	182	92.9%	Other vs. None	4.30 (0.88,21.03)	0.104
	Enlisted Groundcrew	n	403		535				
		Number/%							
		Ear, Face, Head, and Neck	15	3.7%	21	3.9%	Overall		0.857
		Other Sites	7	1.7%	7	1.3%	EFHN vs. None	0.95 (0.48,1.87)	0.999
		No Cancer	381	94.5%	507	94.8%	Other vs. None	1.33 (0.46,3.83)	0.786

TABLE 10-8. (continued)

Unadjusted Analysis of Basal Cell Carcinoma and Sun Exposure-Related Malignant Neoplasms
on the Ear, Face, Head, and Neck or Other Sites by Occupation
(Nonblacks Only)

Cell Type (Status)	Occupation	Statistic	Group				Contrast	Est. Relative Risk (95% C.I.)	p-Value
			Ranch Hand		Comparison				
Basal Cell Carcinoma (Verified and Suspected)	Officer	n	372		488				
		Number/%							
		Ear, Face, Head, and Neck	30	8.1%	27	5.5%	Overall		0.176
		Other Sites	11	3.0%	9	1.8%	EFHN vs. None	1.52 (0.89,2.60)	0.167
		No Cancer	331	89.0%	452	92.6%	Other vs. None	1.67 (0.68,4.07)	0.364
	Enlisted Flyer	n	163		196				
		Number/%							
		Ear, Face, Head, and Neck	9	5.5%	13	6.6%	Overall		0.133
		Other Sites	7	4.3%	2	1.0%	EFHN vs. None	0.85 (0.36,2.05)	0.898
		No Cancer	147	90.2%	181	92.4%	Other vs. None	4.31 (0.88,21.06)	0.104
	Enlisted Groundcrew	n	403		535				
		Number/%							
		Ear, Face, Head, and Neck	15	3.7%	22	4.1%	Overall		0.917
		Other Sites	7	1.7%	8	1.5%	EFHN vs. None	0.90 (0.46,1.77)	0.906
		No Cancer	381	94.5%	505	94.4%	Other vs. None	1.16 (0.42,3.23)	0.974

TABLE 10-8. (continued)

Unadjusted Analysis of Basal Cell Carcinoma and Sun Exposure-Related Malignant Neoplasms
on the Ear, Face, Head, and Neck or Other Sites by Occupation
(Nonblacks Only)

Cell Type (Status)	Occupation	Statistic	Group Ranch Hand		Comparison		Contrast	Est. Relative Risk (95% C.I.)	p-Value
Sun Exposure-Related Malignant Skin Neoplasms (Verified)	Officer	n	372		488				
		Number/%							
		Ear, Face, Head, and Neck	34	9.1%	29	5.9%	Overall		0.078
		Other Sites	13	3.5%	10	2.1%	EFHN vs. None	1.62 (0.97,2.71)	0.088
		No Cancer	325	87.4%	449	92.0%	Other vs. None	1.80 (0.78,4.15)	0.240
	Enlisted Flyer	n	163		196				
		Number/%							
		Ear, Face, Head, and Neck	10	6.1%	12	6.1%	Overall		0.284
		Other Sites	7	4.3%	3	1.5%	EFHN vs. None	1.03 (0.43,2.46)	0.999
		No Cancer	146	89.6%	181	92.4%	Other vs. None	2.89 (0.74,11.38)	0.206
	Enlisted Groundcrew	n	403		535				
		Number/%							
		Ear, Face, Head, and Neck	16	4.0%	22	4.1%	Overall		0.845
		Other Sites	8	2.0%	8	1.5%	EFHN vs. None	0.97 (0.50,1.87)	0.999
		No Cancer	379	94.0%	505	94.4%	Other vs. None	1.33 (0.50,3.58)	0.746

TABLE 10-8. (continued)

Unadjusted Analysis of Basal Cell Carcinoma and Sun Exposure-Related Malignant Neoplasms
on the Ear, Face, Head, and Neck or Other Sites by Occupation
(Nonblacks Only)

Cell Type (Status)	Occupation	Statistic	Group				Contrast	Est. Relative Risk (95% C.I.)	p-Value
			Ranch Hand		Comparison				
Sun Exposure-Related Malignant Skin Neoplasms (Verified and Suspected)	Officer	n	372		488				
		Number/%							
		Ear, Face, Head, and Neck	34	9.1%	30	6.1%	Overall		0.127
		Other Sites	13	3.5%	11	2.3%	EFHN vs. None	1.56 (0.94,2.60)	0.115
		No Cancer	325	87.4%	447	91.6%	Other vs. None	1.63 (0.72,3.67)	0.332
	Enlisted Flyer	n	163		196				
		Number/%							
		Ear, Face, Head, and Neck	11	6.7%	13	6.6%	Overall		0.283
		Other Sites	7	4.3%	3	1.5%	EFHN vs. None	1.05 (0.46,2.41)	0.999
		No Cancer	145	89.0%	180	91.8%	Other vs. None	2.90 (0.74,11.40)	0.206
	Enlisted Groundcrev	n	403		535				
		Number/%							
		Ear, Face, Head, and Neck	16	4.0%	23	4.3%	Overall		0.916
		Other Sites	8	2.0%	9	1.7%	EFHN vs. None	0.92 (0.48,1.77)	0.946
		No Cancer	379	94.0%	503	94.0%	Other vs. None	1.18 (0.45,3.09)	0.920

Abbreviation: EFHN — Ear, Face, Head, and Neck.

For the verified sun exposure-related malignant skin neoplasms, as shown in Table 10-8, the Ranch Hand and Comparison officers displayed a borderline significant difference between their relative frequencies (p=0.078). Ranch Hand frequencies exceeded Comparison frequencies for sun exposure-related malignant skin neoplasms on the ear, face, head, and neck (9.1% vs. 5.9%) and other sites (3.5% vs. 2.1%). The relative frequencies of sun exposure-related malignant skin neoplasms on the ear, face, head, and neck versus no malignant neoplasm were borderline significantly different (p=0.088) for the Ranch Hand and Comparison officers, with an estimated relative risk of 1.62 (95% C.I.: [0.97, 2.71]). For the set of verified sun exposure-related malignant skin neoplasms, neither the enlisted flyers nor the enlisted groundcrew exhibited a significant group difference (p=0.284 and p=0.845, respectively). For each occupation, Ranch Hands and Comparisons did not differ significantly on their relative frequencies of verified and suspected sun exposure-related malignant skin neoplasms (officers: p=0.127; enlisted flyers: p=0.283; enlisted groundcrew: p=0.916).

Conditional Analyses

For Ranch Hands with any verified neoplasm, 74.1 percent (157/212) had a verified skin neoplasm; in contrast, the corresponding percentage for the Comparisons was 66.4 percent (156/235). The difference in these proportions was borderline significant (p=0.095). When suspected neoplasms were included, the Ranch Hand percentage was 73.5 percent (158/215) and the Comparison percentage was 66.0 percent (163/247). These two percentages were borderline significantly different (p=0.100).

Fifty-eight percent (91/157) of the Ranch Hands with any verified skin neoplasm had a verified malignant skin neoplasm. The analogous percentage for the Comparisons was 56.4 percent (88/156). These percentages were not significantly different (p=0.870). The inclusion of suspected neoplasms with the verified neoplasms resulted in a Ranch Hand percentage of 58.2 percent (92/158) and a Comparison percentage of 57.7 percent (94/163). Again, these percentages were not significantly different (p=0.999).

For Ranch Hands having a verified malignant skin neoplasm, 85.7 percent (78/91) had a verified basal cell carcinoma. For Comparisons having a verified malignant skin neoplasm, 86.4 percent (76/88) had a verified basal cell carcinoma. The group percentages were not significantly different (p=0.999). For Ranch Hands with a verified or suspected malignant skin neoplasm, 85.9 percent (79/92) had a verified or suspected basal cell carcinoma. For Comparisons with a verified or suspected malignant skin neoplasm, 86.2 percent (81/94) had a verified or suspected basal cell carcinoma. These percentages also were not significantly different (p=0.999).

For Ranch Hands with a verified basal cell carcinoma, 76.9 percent (60/78) had basal cell carcinoma of the ear, face, head, neck, or upper extremities, and 80.3 percent of the Comparisons (61/76) had basal cell carcinoma at these sites. The difference between these percentages was not significant (p=0.758). Corresponding percentages after including suspected basal cell carcinomas were 75.9 percent (60/79) for the Ranch Hands versus 75.3 percent (61/81) for the Comparisons. These percentages also were not significantly different (p=0.999).

For Ranch Hands with verified sun exposure-related malignant skin neoplasms, 76.1 percent (67/88) had these neoplasms on the ear, face, head, neck, or upper extremities, compared to 77.4 percent (65/84) for the Comparisons. These percentages were not significantly different (p=0.990). Combining the verified with the suspected sun exposure-related malignant skin neoplasms resulted in the following percentages for the specified sites of interest: 75.3 percent (67/89) for the Ranch Hands versus 73.0 percent (65/89) for the Comparisons. Again, these percentages were not significantly different (p=0.864).

Multiple Basal Cell Carcinoma

For verified basal cell carcinoma, the Ranch Hand and Comparison groups were compared on the numbers of men having zero, one, or more than one basal cell carcinoma (Comparisons: 1,143, 61, and 15, respectively; Ranch Hands: 860, 54, and 24, respectively). The Ranch Hand and Comparison groups differed significantly (p=0.050), with the Ranch Hands having higher relative frequencies than the Comparisons for one basal cell carcinoma (5.8% vs. 5.0%) and more than one basal cell carcinoma (2.6% vs. 1.2%), and a lower relative frequency than the Comparisons for zero basal cell carcinoma (91.7% vs. 93.8%). Comparing the relative frequencies for those participants with zero basal cell carcinomas versus one verified basal cell carcinoma indicated no difference between the Ranch Hands and the Comparisons (p=0.452). However, the relative frequency for Ranch Hands with zero basal cell carcinomas versus more than one verified basal cell carcinoma was significantly different from that of the Comparisons (p=0.032). This contrast had an estimated relative risk of 2.13 (95% C.I.: [1.11,4.08]).

Analogous comparisons were made for the combined set of verified and suspected basal cell carcinomas. The Ranch Hand and Comparison groups did not differ (p=0.115) on their distributions of participants having zero, one, or multiple verified or suspected basal cell carcinomas (Comparisons: 1,138 [93.4%], 64 [5.3%], and 17 [1.4%], respectively; Ranch Hands: 859 [91.6%], 55 [5.9%], and 24 [2.6%], respectively). For this combined set of malignant neoplasms, the relative frequencies for those participants having zero basal cell carcinomas versus one basal cell carcinoma were not significantly different (p=0.554) between groups; however, the relative frequencies for Ranch Hands and Comparisons with zero basal cell carcinomas versus multiple basal cell carcinomas was marginally significant (p=0.069), with an estimated relative risk of 1.87 (95% C.I.: [1.00,3.50]).

Basal Cell Carcinoma (Covariate Associations)

The presence of basal cell carcinoma was evaluated for association with previously specified covariates using the pooled group data. Basal cell carcinoma was examined for covariate associations based on verified basal cell carcinoma only, and combining verified and suspected basal cell carcinomas. Table G-1 of Appendix G contains the covariate associations for these malignant skin neoplasms.

Age displayed a significant covariate association with the presence of verified basal cell carcinoma (p<0.001). The younger participants (born in or

after 1942) had lower relative frequencies of verified basal cell carcinoma (3.7%) than participants born between 1923 and 1941 (9.5%) or in or before 1922 (9.5%). Age was also strongly associated with the set of verified and suspected basal cell carcinomas (p<0.001).

For verified basal cell carcinoma, occupation exhibited a significant covariate association (p=0.015). The relative frequency of verified basal cell carcinoma was highest among the officers (8.7%), slightly lower for the enlisted flyers (8.1%), and lowest among the enlisted groundcrew (5.3%). For the set of verified and suspected basal cell carcinomas, occupation was also significant (p=0.014).

Average lifetime residential latitude also exhibited significant covariate relationships with the presence of basal carcinoma (p=0.010 for the verified set; p=0.006 for the verified and suspected set). For participants with an average lifetime residential latitude below 37 degrees, 8.7 percent had a verified basal cell carcinoma, compared to 5.8 percent for participants with average lifetime residential latitudes at or above 37 degrees. Average lifetime residential latitude has also been identified as a possible confounding variable because it is associated with group as well as basal cell carcinoma (i.e., 57.4% of the nonblack Ranch Hands had average lifetime residential latitudes at or above 37 degrees, whereas the nonblack Comparisons were almost equally divided above and below an average lifetime residential latitude of 37 degrees; see Chapter 2). Because of the confounding effect of the latitude variable, an analysis was performed to evaluate this variable for misclassification or bias. Similar to analyses performed for the 1985 followup study, total residential years and chronologic age were evaluated for underreporting and overreporting. No significant group difference was found between total residential years and chronologic age (p=0.912).

Ionizing radiation exposure also displayed a significant association with basal cell carcinoma (p=0.048 for the verified set; p=0.026 for the verified and suspected set). For participants exposed to ionizing radiation, 9.3 percent had a verified basal cell carcinoma, compared to 6.5 percent of the participants not exposed to ionizing radiation.

For ethnic background, there was a borderline significant association for the set of verified basal cell carcinomas (p=0.092). For the ethnic group categories defined in Table 10-1, the following percentages of participants with verified basal cell carcinoma were obtained: 7.9 percent for group A, 6.1 percent for Group B, 1.7 percent for Group C, and 0.0 percent for groups D and E.

A marginally significant association was found between skin color and verified and suspected basal cell carcinoma (p=0.075). For the skin color categories listed in Table 10-1, percentages of participants with verified and suspected basal cell carcinoma were determined for the following skin tones: 0.0 percent for dark; 2.7 percent for medium; 4.6 percent for pale; 8.2 percent for dark peach; and 8.4 percent for pale peach.

Significant associations were found between hair color and basal cell carcinoma (p=0.013 for verified; p=0.006 for verified and suspected). Percentages of participants with verified basal carcinoma were determined for the following hair colors: 7.0 percent for black; 5.5 percent for dark brown; 9.2 percent for light brown; 10.4 percent for blonde; and 18.8 percent for red.

Assuming several preceding episodes of sun exposure, the covariate assessing skin reaction after at least 2 hours sun exposure exhibited a significant association with basal cell carcinoma ($p < 0.001$ for verified; $p < 0.001$ for verified and suspected). For participants having no reaction, 4.1 percent had a verified basal carcinoma; for those that became red, 7.4 percent had a verified basal cell carcinoma; for participants that burned, 14.1 percent had a verified basal cell carcinoma; and for those that burned painfully, 9.3 percent had a verified basal cell carcinoma.

Skin reaction after repeated sun exposure displayed a significant covariate association with both the verified, and the verified and suspected, basal cell carcinomas ($p < 0.001$ for both sets). For participants that tanned deep brown, 4.5 percent had a verified basal cell carcinoma; for those that tanned moderately, 7.5 percent had a verified basal cell carcinoma; for those that tanned mildly, 9.1 percent had a verified basal cell carcinoma; and for those that had freckles with no tan, 23.4 percent had a verified basal cell carcinoma.

For the composite sun reaction index, there was a significant association with both the verified, and the verified and suspected, basal cell carcinomas ($p < 0.001$ for both sets). For those participants having a low composite sun reaction index, 5.5 percent had a verified basal cell carcinoma; for participants with a medium sun reaction index, 11.2 percent had a verified basal cell carcinoma; and for those having a high composite sun reaction index, 11.9 percent had a verified basal cell carcinoma.

Basal Cell Carcinoma (Adjusted Group Contrast Analyses)

As described in the preceding paragraphs, a number of the covariates and host factors were found to be associated with the presence of basal cell carcinoma. In addition, the host factors of hair color, skin color, and ethnic background were implicitly related to the reaction of the skin to the sun. Because of these multiple relationships and because a reduced set of covariates was needed for the adjusted analyses, two main effects statistical models of basal cell carcinoma on selected covariates were implemented. The first model included the following covariates and host factors: occupation, age, skin reaction after at least 2 hours of sun exposure (assuming several preceding episodes), skin reaction after repeated sun exposure, skin color, ethnic background, hair color, ionizing radiation exposure, and average lifetime residential latitude. A second main effects model was used in which the two individual skin reaction variables were replaced by the composite skin reaction index. To simplify the models, the original categories for skin color, hair color, and ethnic background were dichotomized as follows: peach versus not peach for skin color, black or dark brown hair versus other hair colors, and ethnic background group A (English, Welsh, Scottish, or Irish) or group B (Scandanavian, German, Polish, Russian, other Slavic, Jewish, or French) versus the other ethnic groups. The frequencies for the noncollapsed categories of these covariates are described in Table G-1 of Appendix G.

Appendix Table G-2 summarizes the results of the two modeling strategies. Log likelihood values were compared and the model including the individual skin reaction variables (model 1) was chosen. Upon completion of the stepwise procedures to reduce this model, the individual skin reaction variables were

retained along with occupation, age, ethnic background, ionizing radiation
exposure, and average lifetime residential latitude as covariates for the
adjusted group contrast analyses.

The adjusted analysis results for basal cell carcinoma are presented in
Table 10-9. For the verified set of basal cell carcinomas, the significant
group difference (p=0.030) had an adjusted relative risk of 1.46 (95% C.I.:
[1.04,2.06]). For this set of neoplasms, skin reaction after repeated sun
exposure and average lifetime residential latitude were significant covariates
in the model (p=0.011 and p=0.007, respectively). In addition, there was a
significant age-by-ethnic background interaction (p=0.037) and a significant
ionizing radiation-by-skin reaction after at least 2 hours sun exposure
interaction (p=0.045). For the set of verified and suspected basal cell
carcinomas, a borderline significant group difference (p=0.053) had an
adjusted relative risk of 1.39 (95% C.I.: [1.00,1.95]). Skin reaction after
at least 2 hours sun exposure (p<0.001), skin reaction after repeated sun
exposure (p=0.015), average lifetime residential latitude (p=0.006), ionizing
radiation exposure (p=0.043), and an age-by-ethnic background interaction
(p=0.036) were significant terms in the adjusted model.

Sun Exposure-Related Malignant Skin Neoplasms (Covariate Associations)

The presence of sun exposure-related malignant skin neoplasms was
evaluated for association with previously specified covariates using the
pooled group data. These skin neoplasms were examined for covariate
associations based on verified sun exposure-related malignant neoplasms only,
and combining verified and suspected sun exposure-related malignant neoplasms.
Table G-1 of Appendix G contains the covariate associations with these sun
exposure-related malignant skin neoplasms.

Age displayed a significant covariate association with the presence of
verified sun exposure-related malignant skin neoplasms (p<0.001). The younger
participants (born in or after 1942) had lower relative frequencies of veri-
fied sun exposure-related malignant skin neoplasms (4.2%) than participants
born between 1923 and 1941 (10.4%) or in or before 1922 (13.1%). Age was also
strongly associated with the set of verified and suspected sun exposure-
related malignant skin neoplasms (p<0.001).

For verified sun exposure-related malignant skin neoplasms, occupation
exhibited a significant association (p=0.003). The relative frequency of
verified sun exposure-related malignant skin neoplasms was highest among the
officers (10.0%), slightly lower for the enlisted flyers (8.9%), and lowest
among the enlisted groundcrew (5.8%). For the set of verified and suspected
sun exposure-related malignant skin neoplasms, occupation was also
significantly associated (p=0.003).

Average lifetime residential latitude displayed significant covariate
relationships with the presence of sun exposure-related malignant skin
neoplasms (p=0.012 for the verified set; p=0.008 for the verified and
suspected set). For participants with an average lifetime residential
latitude below 37 degrees, 9.6 percent had a verified sun exposure-related
malignant skin neoplasm, compared to 6.6 percent for participants with average
lifetime residential latitudes at or above 37 degrees.

TABLE 10-9.

Adjusted Analysis for Basal Cell Carcinoma and Sun Exposure-Related Malignant Skin Neoplasms by Group
(Nonblacks Only)

Cell Type (Status)	Statistic	Group		Adj. Relative Risk (95% C.I.)	p-Value	Covariate Remarks
		Ranch Hand	Comparison			
Basal Cell Carcinoma (Verified)	n	912	1,184	1.46 (1.04,2.06)	0.030	SUNREPEAT (p=0.011) LAT (p=0.007) AGE*ETHBACK (p=0.037) SUN2HR*RAD (p=0.045)
Basal Cell Carcinoma (Verified and Suspected)	n	912	1,184	1.39 (1.00,1.95)	0.053	SUN2HR (p<0.001) SUNREPEAT (p=0.015) LAT (p=0.006) RAD (p=0.043) AGE*ETHBACK (p=0.036)
Sun Exposure- Related Malignant Skin Neoplasms (Verified)	n	912	1,184	1.48 (1.07,2.04)	0.019	SUN2HR (p<0.001) SUNREPEAT (p=0.002) LAT (p=0.010) AGE*ETHBACK (p=0.032)
Sun Exposure- Related Malignant Skin Neoplasms (Verified and Suspected)	n	912	1,184	1.39 (1.01,1.91)	0.044	SUNREPEAT (p=0.002) AGE*ETHBACK (p=0.028) SUN2HR*LAT (p=0.019)

For asbestos exposure, there was a borderline significant covariate association with the presence of verified sun exposure-related malignant skin neoplasms (p=0.078). However, the covariate association was inversely related to asbestos exposure. For participants exposed to asbestos, 6.1 percent had a verified sun exposure-related malignant skin neoplasm, compared to 8.6 percent for those not exposed to asbestos.

Ionizing radiation exposure also displayed covariate associations with sun exposure-related malignant skin neoplasms (p=0.044 for the verified set; p=0.024 for the verified and suspected set). For participants exposed to ionizing radiation, 10.2 percent had a verified sun exposure-related malignant skin neoplasm, compared to 7.3 percent of the participants not exposed to ionizing radiation.

Self-reported herbicide exposure exhibited a borderline significant covariate relationship with the verified and suspected sun exposure-related malignant skin neoplasms (p=0.098). For participants reporting herbicide exposure, 9.1 percent had a sun exposure-related malignant skin neoplasm, compared to 7.0 percent not reporting herbicide exposure.

For ethnic background, there were significant covariate associations with the presence of sun exposure-related malignant skin neoplasms (p=0.032 for the verified set; p=0.045 for the verified and suspected set). For the ethnic group categories, the following percentages of participants with verified sun exposure-related malignant skin neoplasms were obtained: 9.0 percent for group A; 6.3 percent for Group B; 1.7 percent for Group C; and 0.0 percent for groups D and E.

A marginally significant association was found between skin color and verified and suspected sun exposure-related malignant skin neoplasms (p=0.088). Percentages of participants with verified and suspected sun exposure-related malignant skin neoplasms were determined for the following skin tones: 0.0 percent for dark; 2.7 percent for medium; 5.7 percent for pale; 8.8 percent for dark peach; and 9.6 percent for pale peach.

Significant associations were found between hair color and sun exposure-related malignant skin neoplasms (p=0.003 for verified; p=0.001 for verified and suspected). Percentages of participants with verified sun exposure-related malignant skin neoplasms were determined for the following hair colors: 7.7 percent for black; 6.0 percent for dark brown; 10.8 percent for light brown; 11.3 percent for blonde; and 18.8 percent for red.

For skin reaction to sun exposure after at least 2 hours (assuming several preceding episodes of sun exposure), significant associations were found for sun exposure-related malignant skin neoplasms (p<0.001 for verified; p<0.001 for verified and suspected). For participants having no reaction, 4.7 percent had a verified sun exposure-related malignant skin neoplasm; for those that became red, 8.4 percent had a verified sun exposure-related malignant skin neoplasm; for participants that burned, 15.5 percent had this type of neoplasm; and for those that burned painfully, 9.3 percent had a verified sun exposure-related malignant skin neoplasm.

Skin reaction after repeated sun exposure displayed a significant covariate association with both the verified, and the verified and suspected,

sun exposure-related malignant skin neoplasms (p<0.001 for both sets). For participants who tanned deep brown, 5.1 percent had a verified sun exposure-related malignant skin neoplasm; for those who tanned moderately, 8.2 percent had a verified sun exposure-related malignant skin neoplasm; for those who tanned mildly, 10.7 percent had this form of neoplasm; and for those who had freckles with no tan, 27.7 percent had this type of malignant condition.

For the composite sun reaction index, there were significant covariate associations for both the verified, and the verified and suspected, sun exposure-related malignant skin neoplasms (p<0.001 for both sets). For those participants having a low composite sun reaction index, 6.2 percent had a verified sun exposure-related malignant skin neoplasm; for participants with a medium sun reaction index, 12.4 percent had a verified sun exposure-related malignant skin neoplasm; and for those having a high composite sun reaction index, 13.1 percent had a verified sun exposure-related malignant skin neoplasm.

Sun Exposure-Related Malignant Skin Neoplasms (Adjusted Group Contrast Analyses)

The adjusted analysis results for sun exposure-related malignant neoplasms are presented in Table 10-9. For the set of verified sun exposure-related malignant skin neoplasms, the adjusted contrast of the Ranch Hands and Comparisons was significant (p=0.019), with an adjusted relative risk of 1.48 (95% C.I.: [1.07,2.04]). For the adjusted model, the significant covariates were skin reaction after at least 2 hours exposure (p<0.001) and repeated sun exposure (p=0.002), and average lifetime residential latitude (p=0.010). The age-by-ethnic background interaction was again significant (p=0.032). For the combined set of verified and suspected sun exposure-related malignant skin neoplasms, the significant adjusted group contrast (p=0.044) had an adjusted relative risk of 1.39 (95% C.I.: [1.01,1.91]). For this analysis, repeated sun exposure was a significant covariate (p=0.002); there was a significant age-by-ethnic background interaction (p=0.028) and a significant interaction between the covariates for skin reaction after at least 2 hours sun exposure and average lifetime residential latitude (p=0.019).

Systemic Neoplasms

Ranch Hands and Comparisons were compared on their relative frequencies of systemic neoplasms for the following three groups of analyses: behavior; malignant neoplasms by location/site; and malignant systemic neoplasms conditioned on the presence of any systemic neoplasm. For malignant systemic neoplasms, covariate associations and adjusted group analysis were performed.

Behavior

Table 10-10 displays the distribution of Ranch Hands and Comparisons having malignant systemic neoplasms, benign systemic neoplasms, systemic neoplasms of uncertain behavior or unspecified nature, and all systemic neoplasms. Results are presented for verified systemic neoplasms and for verified and suspected systemic neoplasms.

TABLE 10-10.

Unadjusted Analysis for Systemic Neoplasms by Behavior, Status, and Group

Behavior (Status)	Statistic	Group Ranch Hand		Comparison		Est. Relative Risk (95% C.I.)	p-Value
Malignant (Verified)	n	995		1,299			
	Number/%						
	Yes	21	2.1%	21	1.6%	1.31 (0.71,2.42)	0.472
	No	974	97.9%	1,278	98.4%		
Malignant (Verified and Suspected)	n	995		1,299			
	Number/%						
	Yes	21	2.1%	23	1.8%	1.20 (0.66,2.17)	0.660
	No	974	97.9%	1,276	98.2%		
Benign (Verified)	n	995		1,299			
	Number/%						
	Yes	55	5.5%	69	5.3%	1.04 (0.73,1.50)	0.892
	No	940	94.5%	1,230	94.7%		
Benign (Verified and Suspected)	n	995		1,299			
	Number/%						
	Yes	55	5.5%	71	5.5%	1.01 (0.71,1.45)	0.999
	No	940	94.5%	1,228	94.5%		
Uncertain Behavior or Unspecified Nature (Verified)	n	995		1,299			
	Number/%						
	Yes	5	0.5%	8	0.6%	0.82 (0.27,2.50)	0.948
	No	990	99.5%	1,291	99.4%		

TABLE 10-10. (continued)

Unadjusted Analysis for Systemic Neoplasms by Behavior, Status, and Group

Behavior (Status)	Statistic	Group				Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand		Comparison			
Uncertain	n	995		1,299			
Behavior or	Number/%						
Unspecified	Yes	7	0.7%	11	0.9%	0.83 (0.32,2.15)	0.892
Nature	No	988	99.3%	1,288	99.1%		
(Verified and							
Suspected)							
All	n	995		1,299			
(Verified)	Number/%						
	Yes	80	8.0%	97	7.5%	1.08 (0.80,1.48)	0.666
	No	915	92.0%	1,202	92.5%		
All	n	995		1,299			
(Verified and	Number/%						
Suspected)	Yes	82	8.2%	104	8.0%	1.03 (0.76,1.40)	0.896
	No	913	91.8%	1,195	92.0%		

For malignant systemic neoplasms, Ranch Hands and Comparisons were not significantly different for the unadjusted analyses (p=0.472 for verified; p=0.660 for verified and suspected). Ranch Hands and Comparisons also did not differ significantly for the unadjusted analyses of benign systemic neoplasms (p=0.892 for verified; p=0.999 for verified and suspected). The Ranch Hand and Comparison unadjusted group contrasts for systemic neoplasms of uncertain behavior or unspecified nature were not significant (p=0.948 for verified; p=0.892 for verified and suspected).

The unadjusted analysis comparing Ranch Hands and Comparisons for all systemic neoplasms (malignant, benign, and uncertain behavior or unspecified nature) also did not exhibit a significant group difference (p=0.666 for verified; p=0.896 for verified and suspected).

Malignant Neoplasms by Location/Site

Table 10-11 summarizes the distributions of Ranch Hands and Comparisons having malignant systemic neoplasms by location/site. The statistical power for detecting group differences on the frequency of systemic neoplasms at specified sites is low. Results are presented both for verified, and verified and suspected, systemic neoplasms when appropriate. The results presented in Table 10-11 incorporate corrections to the 1985 followup data that were made after additional medical records were obtained (see Table 10-9 on page 10-26 and Table 10-17 on page 10-44 of the 1985 followup report). In the 1985 followup report, one Ranch Hand was counted as having a verified malignant systemic neoplasm of the eye. This was actually a skin neoplasm of the eyelid. The 1985 followup report also counted one Ranch Hand and one Comparison with verified malignant systemic neoplasms of ill-defined sites; both of these were subsequently verified as skin neoplasms. In addition, two Ranch Hands, instead of three Ranch Hands, had verified systemic testicular cancer. At the 1987 followup, an additional Ranch Hand was diagnosed as having testicular cancer, bringing the Ranch Hand total back to three cases (see Table 10-11). Also in the 1985 followup report (Table 10-9), one of the Ranch Hand bronchus and lung suspected systemic neoplasms should have been included in the Comparison group.

For verified malignant systemic neoplasms of the oral cavity, pharynx, and larynx, the unadjusted analysis comparing Ranch Hands and Comparisons was not significant (p=0.440). Ranch Hands and Comparisons did not differ significantly for the unadjusted analysis comparing the distributions of participants having verified malignant systemic neoplasms of the thyroid (p=0.999). For the unadjusted group contrast of verified, and verified and suspected, malignant systemic neoplasms of the bronchus and lung, there were no significant differences (p=0.999 and p=0.999, respectively).

For verified malignant systemic neoplasms of the colon and rectum, the distributions of Ranch Hands and Comparisons were not significantly different (p=0.836). The unadjusted group contrast comparing the distributions of Ranch Hands and Comparisons for verified malignant systemic neoplasms of the kidney and bladder was not significant (p=0.460). The unadjusted group contrast for Ranch Hands and Comparisons were not significant for verified malignant systemic neoplasms of the prostate, testicles, or penis (p=0.698, 0.162, and 0.999, respectively). For malignant systemic neoplasms of ill-defined sites, Ranch Hands and Comparisons did not differ significantly for the verified and

TABLE 10-11.

Unadjusted Analysis for Malignant Systemic Neoplasms by Location/Site, Status, and Group

Location/Site (Status)	Statistic	Group				Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand		Comparison			
Oral Cavity, Pharynx, and Larynx (Verified*)	n	995		1,299			
	Number/%						
	Yes	3	0.3%	1	0.1%	3.93 (0.41,37.79)	0.440
	No	992	97.7%	1,298	99.9%		
Thyroid (Verified*)	n	995		1,299			
	Number/%						
	Yes	0	0.0%	1	0.1%	--[a]	0.999
	No	995	100.0%	1,298	99.9%		
Bronchus and Lung (Verified)	n	995		1,299			
	Number/%						
	Yes	3	0.3%	3	0.2%	1.31 (0.26,6.49)	0.999
	No	992	99.7%	1,296	99.8%		
Bronchus and Lung (Verified and Suspected)	n	995		1,299			
	Number/%						
	Yes	3	0.3%	4	0.3%	0.98 (0.22,4.39)	0.999
	No	992	99.7%	1,295	99.7%		
Colon and Rectum (Verified*)	n	995		1,299			
	Number/%						
	Yes	1	0.1%	3	0.2%	0.44 (0.05,4.18)	0.836
	No	994	99.9%	1,296	99.8%		

TABLE 10-11. (continued)

Unadjusted Analysis for Malignant Systemic Neoplasms by Location/Site, Status, and Group

Location/Site (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Kidney and Bladder (Verified*)	n	995	1,299		
	Number/%				
	Yes	5 0.5%	3 0.2%	2.18 (0.52,9.15)	0.460
	No	990 99.5%	1,296 99.8%		
Prostate (Verified*)	n	995	1,299		
	Number/%				
	Yes	2 0.2%	5 0.4%	0.52 (0.10,2.69)	0.698
	No	993 99.8%	1,294 99.6%		
Testicles (Verified*)	n	995	1,299		
	Number/%				
	Yes	3 0.3%	0 0.0%	--ª	0.162
	No	992 99.7%	1,299 100.0%		
Hodgkin's Disease (Verified*)	n	995	1,299		
	Number/%				
	Yes	0 0.0%	1 0.1%	--ª	0.999
	No	995 100.0%	1,298 99.9%		
Ill-Defined Sites (Verified and Suspected**)	n	995	1,299		
	Number/%				
	Yes	0 0.0%	1 0.1%	--ª	0.999
	No	995 100.0%	1,298 99.9%		

TABLE 10-11. (continued)

Unadjusted Analysis for Malignant Systemic Neoplasms by Location/Site, Status, and Group

Location/Site (Status)	Statistic	Group Ranch Hand	Comparison	Est. Relative Risk (95% C.I.)	p-Value
Thymus and Mediastinum (Verified*)	n Number/% Yes No	995 2 0.2% 993 99.8%	1,299 0 0.0% 1,299 100.0%	--[a]	0.376
Head, Face, and Neck (Verified*)	n Number/% Yes No	995 0 0.0% 995 100.0%	1,299 1 0.1% 1,298 99.9%	--[a]	0.999
Brain (Verified*)	n Number/% Yes No	995 0 0.0% 995 100.0%	1,299 1 0.1% 1,298 99.9%	--[a]	0.999
Other Malignant Neoplasms of Lymphoid and Histiocytic Tissue (Verified*)	n Number/% Yes No	995 2 0.2% 993 99.8%	1,299 1 0.1% 1,298 99.9%	2.61 (0.24,28.87)	0.802
Leukemia (Verified*)	n Number/% Yes No	995 1 0.1% 994 99.9%	1,299 0 0.0% 1,299 100.0%	--[a]	0.868

TABLE 10-11. (continued)

Unadjusted Analysis for Malignant Systemic Neoplasms by Location/Site, Status, and Group

Location/Site (Status)	Statistic	Group		Est. Relative Risk (95% C.I.)	p-Value
		Ranch Hand	Comparison		
Carcinoma In Situ of Penis (Verified*)	n Number/% Yes No	995 0 0.0% 995 100.0%	1,299 1 0.1% 1,298 99.9%	--ᵃ	0.999
Carcinoma In Situ of Other Specified Sites (Verified*)	n Number/% Yes No	995 1 0.1% 994 99.9%	1,299 0 0.0% 1,299 100.0%	--ᵃ	0.868

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

--ᵃEstimated relative risk/confidence interval/p-value not given due to cell with zero frequency.

**No verified malignant neoplasms.

suspected neoplasms (p=0.999). The distribution of Ranch Hands having verified malignant systemic neoplasms of the thymus and mediastinum was not significantly different from that of the Comparisons (p=0.376).

For the head, face, and neck, Ranch Hands and Comparisons did not differ with respect to the occurrence of verified malignant systemic neoplasms (p=0.999). The Comparison had a verified fibrosarcoma of the neck. Ranch Hands and Comparisons did not differ significantly on their relative frequencies of verified malignant systemic neoplasms of the brain (p=0.999).

For the verified set of other malignant neoplasms of lymphoid and histiocytic tissue, Ranch Hands did not differ significantly from the Comparisons (p=0.802). One Ranch Hand had a verified NHL. For verified leukemia and Hodgkin's Disease, the unadjusted group contrasts of Ranch Hands versus Comparisons were not significant (p=0.868 and 0.999, respectively).

For verified carcinoma in situ of other and unspecified sites, the unadjusted group contrast was not significant (p=0.868).

Conditional Analyses

For participants with any verified systemic neoplasm (malignant, benign, uncertain behavior, or unspecified nature), 26.3 percent (21/80) of the Ranch Hands had malignant systemic neoplasms, compared to 21.6 percent (21/97) for the Comparison group. These percentages were not significantly different (p=0.590). Combining the verified and suspected systemic neoplasms, the corresponding Ranch Hand and Comparison percentages were 25.6 percent (21/82) and 22.1 percent (23/104), respectively. These percentages also were not statistically different (p=0.700).

Malignant Systemic Neoplasms (Covariate Associations)

All covariates described in Table 10-1 were investigated for associations with malignant systemic neoplasms, except average lifetime residential latitude and the host factors of ethnic background, skin color, hair color, eye color, and skin reactions to sun exposure. As noted previously, race was included among the candidate covariates for the malignant systemic neoplasms. Appendix Table G-1 contains the results of the covariate association analyses.

Age displayed significant covariate associations for both the verified malignant systemic neoplasms (p<0.001) and the verified and suspected malignant systemic neoplasms (p<0.001). For both sets, the relative frequency of malignant systemic neoplasms increased with age. Participants born in or after 1942 had lower relative frequencies of verified malignant systemic neoplasms (0.7%) than participants born between 1923 and 1941 (2.2%) or in or before 1922 (8.3%).

Occupation exhibited marginally significant associations with malignant systemic neoplasms (p=0.075 for verified; p=0.060 for verified and suspected). For verified malignant systemic neoplasms, the officers had the highest relative frequency (2.6%), followed by the enlisted flyers (1.6%), and then the enlisted groundcrew (1.3%).

Lifetime alcohol history displayed significant associations with malignant systemic neoplasms (p=0.041 for verified; p=0.010 for verified and suspected). For verified malignant systemic neoplasms, the relative frequency was highest for participants with more than 40 drink-years (0 drink-years: 1.5%; over 0 drink-years and not exceeding 40 drink-years: 1.4%; over 40 drink-years: 3.1%).

Although lifetime cigarette smoking history (p=0.198 for verified; p=0.208 for verified and suspected) and race (p=0.546 for verified; p=0.500 for verified and suspected) did not display significant associations with malignant systemic neoplasms, these covariates were also included in the adjusted systemic analyses because for some types of systemic neoplasms these covariates are known risk factors. Other covariates used for the adjusted analyses were: age, occupation, and lifetime alcohol history.

Malignant Systemic Neoplasms (Adjusted Group Contrast Analyses)

The adjusted analysis results for malignant systemic neoplasms are presented in Table 10-12. The Ranch Hand and Comparison groups did not differ for either the verified set of malignant systemic neoplasms (p=0.525) or the verified and suspected set of malignant systemic neoplasms (p=0.731). For verified malignant systemic neoplasms, age and lifetime alcohol history were significant covariates (p<0.001 and p=0.010, respectively). Similarly, for the verified and suspected malignant systemic neoplasms, age and lifetime alcohol history were significant covariates in the model (p<0.001 and p=0.006, respectively).

Skin and Systemic Neoplasms

Unadjusted analyses were performed for the combined set of all skin and all systemic neoplasms. For these analyses all 2,294 participants were used (i.e., Black participants were not excluded). For the verified skin and verified systemic neoplasms presented in Table 10-13, the Ranch Hand and Comparison groups differed significantly (p=0.032), with an estimated relative risk of 1.26 (95% C.I.: [1.03,1.54]). The relative frequencies for the combined set of verified skin and verified systemic neoplasms were 22.5 percent for the Ranch Hands and 18.8 percent for the Comparisons. For the verified and suspected set of skin and systemic neoplasms, the Ranch Hand and Comparison group contrast was borderline significant (p=0.079), with an estimated relative risk of 1.20 (95% C.I.: [0.98,1.47]). The relative frequencies of verified and suspected skin and systemic neoplasms for Ranch Hands and Comparisons were 22.8 percent and 19.7 percent, respectively.

Table 10-13 also presents unadjusted analyses comparing Ranch Hands and Comparisons on the frequency of nonverifiable skin and systemic neoplasms. The Ranch Hand and Comparison group contrast was not significant (p=0.744), indicating that the frequency of unverified reports of malignancy did not differ in the two groups.

TABLE 10-12.

Adjusted Analysis for Malignant Systemic Neoplasms by Status and Group

Variable (Status)	Statistic	Group		Adj. Relative Risk (95% C.I.)	p-Value	Covariate Remarks
		Ranch Hand	Comparison			
Malignant Systemic Neoplasms (Verified)	n	985	1,296	1.23 (0.66,2.29)	0.525	AGE (p<0.001) DRKYR (p=0.010)
Malignant Systemic Neoplasms (Verified and Suspected)	n	985	1,296	1.11 (0.60,2.06)	0.731	AGE (p<0.001) DRKYR (p=0.006)

TABLE 10-13.

Unadjusted Analysis for Verified, Suspected, and Nonverifiable
Skin and Systemic Neoplasms by Group

Variable	Statistic	Group Ranch Hand		Comparison		Est. Relative Risk (95% C.I.)	p-Value
All Skin and Systemic (Verified)	n Number/% Yes No	995 224 771	22.5% 77.5%	1,299 244 1,055	18.8% 81.2%	1.26 (1.03,1.54)	0.032
All Skin and Systemic (Verified and Suspected)	n Number/% Yes No	995 227 768	22.8% 77.2%	1,299 256 1,043	19.7% 80.3%	1.20 (0.98,1.47)	0.079
Nonverifiable Neoplasm	n Number/% Yes No	995 23 972	2.3% 97.7%	1,299 34 1,265	2.6% 97.4%	--	0.744

--Relative risk and associated confidence interval not appropriate.

Exposure Index Analysis

Table 10-14 summarizes, within each occupational stratum, the unadjusted results comparing the relative frequencies of basal cell carcinoma, sun exposure-related malignant skin neoplasms, and malignant systemic neoplasms in the Ranch Hand group across exposure categories. For basal cell carcinoma, sun exposure-related malignant skin neoplasms, and malignant systemic neoplasms, Table 10-15 summarizes by occupation the adjusted exposure index analyses for the Ranch Hands. The covariates, in addition to exposure index, included in the adjusted analysis models for basal cell carcinoma and sun exposure-related malignant skin neoplasms were age, skin reaction after at least 2 hours sun exposure (assuming several preceding episodes of sun exposure) and after repeated sun exposure, ethnic background, average lifetime residential latitude, and ionizing radiation exposure. The covariates, in addition to exposure index, included in the adjusted analysis models for malignant systemic neoplasms were age, race, lifetime cigarette smoking history, and lifetime alcohol history. Models investigated also included the exposure index-by-covariate interaction terms.

The final interpretation of the exposure index data must await the reanalysis of the clinical data using the results of the serum dioxin assay. The report is expected in 1991.

Skin Neoplasms

Basal Cell Carcinoma

For the unadjusted analysis of the enlisted flyers presented in Table 10-14, the frequencies of verified basal cell carcinoma were borderline significant across the three exposure levels (p=0.067). However, the relative frequency was highest in the low exposure group. For this set of neoplasms, the contrast of the Ranch Hand frequency for the medium exposure group to the frequency for the low exposure group was also marginally significant (p=0.088). The medium versus low exposure contrast had an estimated relative risk of 0.27 (95% C.I.: [0.07,1.05]). For officers and for enlisted groundcrew, the relative frequencies of verified basal cell carcinoma did not differ significantly across exposure categories. For unadjusted analyses on the set of verified and suspected basal cell carcinomas, the difference for the enlisted flyers across the three exposure levels was more pronounced (p=0.031). However, the low exposure group again had the higher frequency of basal cell carcinomas. The contrast of the Ranch Hand enlisted flyers in the medium and low exposure categories was significant (p=0.050), with an estimated relative risk of 0.24 (95% C.I.: [0.06,0.91]). The corresponding contrast for the high and low exposure categories was borderline significant (p=0.098) with an estimated relative risk of 0.28 (95% C.I.: [0.07,1.09]). No significant differences were found for officers or enlisted groundcrew on the relative frequency of verified and suspected basal cell carcinoma across the exposure index categories.

Table 10-15 shows that for the Ranch Hand officers and enlisted groundcrew, there were no significant differences among the exposure levels for either the verified basal cell carcinomas or the verified and suspected

TABLE 10-14.

Unadjusted Exposure Index for Malignancy Variables by Occupation

Variable	Occupation	Statistic	Exposure Index Low		Exposure Index Medium		Exposure Index High		Exposure Index Contrast	Est. Relative Risk (95% C.I.)	p-Value
Basal Cell Carcinoma (Verified)[a]	Officer	n Number/%	128		121		123		Overall		0.556
		Yes	11	8.6%	15	12.4%	15	12.2%	M vs. L	1.51 (0.66,3.42)	0.440
		No	117	91.4%	106	87.6%	108	87.8%	H vs. L	1.48 (0.65,3.36)	0.466
	Enlisted Flyer	n Number/%	54		59		50		Overall		0.067
		Yes	9	16.7%	3	5.1%	3	6.0%	M vs. L	0.27 (0.07,1.05)	0.088
		No	45	83.3%	56	94.9%	47	94.0%	H vs. L	0.32 (0.08,1.26)	0.160
	Enlisted Groundcrew	n Number/%	131		144		128		Overall		0.615
		Yes	9	6.9%	6	4.2%	7	5.5%	M vs. L	0.59 (0.20,1.70)	0.472
		No	122	93.1%	138	95.8%	121	94.5%	H vs. L	0.78 (0.28,2.17)	0.834
Basal Cell Carcinoma (Verified and Suspected)[a]	Officer	n Number/%	128		121		123		Overall		0.556
		Yes	11	8.6%	15	12.4%	15	12.2%	M vs. L	1.51 (0.66,3.42)	0.440
		No	117	91.4%	106	87.6%	108	87.8%	H vs. L	1.48 (0.65,3.36)	0.466
	Enlisted Flyer	n Number/%	54		59		50		Overall		0.031
		Yes	10	18.5%	3	5.1%	3	6.0%	M vs. L	0.24 (0.06,0.91)	0.050
		No	44	81.5%	56	94.9%	47	94.0%	H vs. L	0.28 (0.07,1.09)	0.098
	Enlisted Groundcrew	n Number/%	131		144		128		Overall		0.615
		Yes	9	6.9%	6	4.2%	7	5.5%	M vs. L	0.59 (0.20,1.70)	0.472
		No	122	93.1%	138	95.8%	121	94.5%	H vs. L	0.78 (0.28,2.17)	0.834

TABLE 10-14. (continued)

Unadjusted Exposure Index for Malignancy Variables by Occupation

Variable	Occupation	Statistic	Exposure Index Low		Medium		High		Exposure Index Contrast	Est. Relative Risk (95% C.I.)	p-Value
Sun Exposure- Related Malignant Skin Neoplasms (Verified)[a]	Officer	n	128		121		123		Overall		0.636
		Number/%									
		Yes	14	10.9%	18	14.9%	15	12.2%	M vs. L	1.42 (0.67,3.01)	0.460
		No	114	89.1%	103	85.1%	108	87.8%	H vs. L	1.13 (0.52,2.45)	0.908
	Enlisted Flyer	n	54		59		50		Overall		0.059
		Number/%									
		Yes	10	18.5%	4	6.8%	3	6.0%	M vs. L	0.32 (0.09,1.09)	0.106
		No	44	81.5%	55	93.2%	47	94.0%	H vs. L	0.28 (0.07,1.09)	0.098
	Enlisted Groundcrew	n	131		144		128		Overall		0.865
		Number/%									
		Yes	9	6.9%	8	5.6%	7	5.5%	M vs. L	0.80 (0.30,2.13)	0.838
		No	122	93.1%	136	94.4%	121	94.5%	H vs. L	0.78 (0.28,2.17)	0.834
Sun Exposure- Related Malignant Skin Neoplasms (Verified and Suspected)[a]	Officer	n	128		121		123		Overall		0.636
		Number/%									
		Yes	14	10.9%	18	14.9%	15	12.2%	M vs. L	1.42 (0.67,3.01)	0.460
		No	114	89.1%	103	85.1%	108	87.8%	H vs. L	1.13 (0.52,2.45)	0.908
	Enlisted Flyer	n	54		59		50		Overall		0.028
		Number/%									
		Yes	11	20.4%	4	6.8%	3	6.0%	M vs. L	0.28 (0.09,0.96)	0.062
		No	43	79.6%	55	93.2%	47	94.0%	H vs. L	0.25 (0.07,0.96)	0.060
	Enlisted Groundcrew	n	131		144		128		Overall		0.865
		Number/%									
		Yes	9	6.9%	8	5.6%	7	5.5%	M vs. L	0.80 (0.30,2.13)	0.838
		No	122	93.1%	136	94.4%	121	94.5%	H vs. L	0.78 (0.28,2.17)	0.834

TABLE 10-14. (continued)

Unadjusted Exposure Index for Malignancy Variables by Occupation

Variable	Occupation	Statistic	Exposure Index						Exposure Index Contrast	Est. Relative Risk (95% C.I.)	p-Value
			Low		Medium		High				
Malignant Systemic Neoplasms (Verified*)	Officer	n Number/%	130		124		125		Overall		0.464
		Yes	2	1.5%	3	2.4%	5	4.0%	M vs. L	1.59 (0.26,9.66)	0.956
		No	128	98.5%	121	97.6%	120	96.0%	H vs. L	2.67 (0.51,14.01)	0.414
	Enlisted Flyer	n Number/%	55		63		53		Overall		0.393
		Yes	2	3.6%	2	3.2%	0	0.0%	M vs. L	0.87 (0.12,6.38)	0.999
		No	53	96.4%	61	96.8%	53	100.0%	H vs. L	--[b]	0.514
	Enlisted Groundcrew	n Number/%	147		158		140		Overall		0.135
		Yes	1	0.7%	5	3.2%	1	0.7%	M vs. L	4.77 (0.55,41.33)	0.250
		No	146	99.3%	153	96.8%	139	99.3%	H vs. L	1.05 (0.07,16.96)	0.999

[a]Nonblacks only.

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

--[b]Estimated relative risk and confidence interval not given due to cell with zero frequency.

TABLE 10-15.

Adjusted Exposure Index for Malignancy Variables by Occupation

Variable	Occupation	Statistic	Exposure Index			Exposure Index Contrast	Adj. Relative Risk (95% C.I.)	p-Value
			Low	Medium	High			
Basal Cell Carcinoma (Verified)[a]	Officer	n	128	118	119	Overall		0.753
						M vs. L	1.37 (0.57,3.28)	0.480
						H vs. L	1.30 (0.54,3.10)	0.561
	Enlisted Flyer	n	49	56	49	Overall		0.058**
						M vs. L	0.21 (0.05,1.01)**	0.051**
						H vs. L	0.26 (0.06,1.18)**	0.080**
	Enlisted Groundcrew	n	126	140	127	Overall		0.673
						M vs. L	0.64 (0.21,1.90)	0.420
						H vs. L	0.69 (0.24,1.96)	0.485
Basal Cell Carcinoma (Verified and Suspected)[a]	Officer	n	128	118	119	Overall		0.753
						M vs. L	1.37 (0.57,3.28)	0.480
						H vs. L	1.30 (0.54,3.10)	0.561
	Enlisted Flyer	n	49	56	49	Overall		0.023**
						M vs. L	0.18 (0.04,0.83)**	0.028**
						H vs. L	0.21 (0.05,0.95)**	0.042**
	Enlisted Groundcrew	n	126	140	127	Overall		0.673
						M vs. L	0.64 (0.21,1.90)	0.420
						H vs. L	0.69 (0.24,1.96)	0.485

TABLE 10-15. (continued)

Adjusted Exposure Index for Malignancy Variables by Occupation

Variable	Occupation	Statistic	Exposure Index			Exposure Index Contrast	Adj. Relative Risk (95% C.I.)	p-Value
			Low	Medium	High			
Sun Exposure-Related Malignant Skin Neoplasms (Verified)[a]	Officer	n	128	118	119	Overall		0.762
						M vs. L	1.29 (0.58,2.89)	0.537
						H vs. L	0.98 (0.43,2.26)	0.966
	Enlisted Flyer	n	49	56	49	Overall		0.046**
						M vs. L	0.27 (0.06,1.11)**	0.070**
						H vs. L	0.20 (0.04,0.92)**	0.039**
	Enlisted Groundcrew	n	126	140	127	Overall		0.805
						M vs. L	0.90 (0.33,2.47)	0.834
						H vs. L	0.71 (0.25,2.01)	0.519
Sun Exposure-Related Malignant Skin Neoplasms (Verified and Suspected)[a]	Officer	n	128	118	119	Overall		0.762
						M vs. L	1.29 (0.58,2.89)	0.537
						H vs. L	0.98 (0.43,3.26)	0.966
	Enlisted Flyer	n	49	56	49	Overall		0.017**
						M vs. L	0.22 (0.05,0.92)**	0.038**
						H vs. L	0.16 (0.04,0.75)**	0.020**
	Enlisted Groundcrew	n	126	140	127	Overall		0.805
						M vs. L	0.90 (0.33,2.47)	0.834
						H vs. L	0.71 (0.25,2.01)	0.519

TABLE 10-15. (continued)

Adjusted Exposure Index for Malignancy Variables by Occupation

Variable	Occupation	Statistic	Exposure Index			Exposure Index Contrast	Adj. Relative Risk (95% C.I.)	p-Value
			Low	Medium	High			
Systemic Malignant Neoplasms (Verified*)	Officer	n	129	122	125	Overall		0.536
						M vs. L	1.42 (0.22,9.01)	0.708
						H vs. L	2.43 (0.45,13.00)	0.300
	Enlisted Flyer	n	54	62	53	Overall		0.225
						M vs. L	1.99 (0.17,23.56)^b	0.587^b
						H vs. L	--	--
	Enlisted Groundcrew	n	144	158	138	Overall		0.024**
						M vs. L	8.97 (0.79,101.9)**	0.077**
						H vs. L	0.42 (0.01,13.01)**	0.621**

ᵃNonblacks only.

**Exposure index-by-covariate interaction (0.01<p≤0.05)--relative risk and p-value purposes and derived from a model fitted after deletion of this interaction.

*No suspected malignant neoplasms; therefore, verified and suspected same as verified.

--ᵇRelative risk/confidence interval/p-value not given due to cells with zero frequency.

basal cell carcinomas. However, Table 10-16 summarizes significant exposure
index-by-age interactions for the Ranch Hand enlisted flyers. There were
significant exposure index-by-age interactions for the set of verified basal
cell carcinomas (p=0.027) and verified and suspected basal cell carcinomas
(p=0.043). Appendix Table G-3 summarizes the results of stratifying the
enlisted flyers by age. (Because there were only two Ranch Hands born before
1922 for this occupational cohort, age was dichotomized into born before 1942
and born in or after 1942.) For both sets of basal cell carcinoma analyses,
Ranch Hand enlisted flyers born before 1942 had significantly different
relative frequencies of the skin neoplasms by exposure category (p=0.014 for
verified basal carcinoma; p=0.006 for verified and suspected basal cell
carcinoma). However the relative frequencies were inversely related to the
exposure index (i.e., the low exposure category had the highest relative
frequency). Pairwise contrasts of the medium or high exposure levels with the
low exposure level were also significant or borderline significant, although
the differences were not consistent with a relationship of increasing
exposure. For the enlisted flyer analyses that had significant exposure
index-by-age interactions, a second adjusted analysis was performed without
this interaction. Table 10-15 presents the results of these secondary
analyses. For verified basal cell carcinoma, the group difference for the
enlisted flyers was marginally significant (p=0.058), and for the verified and
suspected set of basal cell carcinoma, the group difference for the enlisted
flyers was significant (p=0.023). Estimated relative risks for the medium
versus low, and the high versus low, contrasts were significant or borderline
significant; however, these relative risks were less than 1 and not supportive
of a dose-response effect.

TABLE 10-16.

Summary of Exposure Index-by-Covariate Interactions
From Adjusted Analyses for Malignancy Variables*

Variable	Occupation	Covariate	p-Value
Basal Cell Carcinoma (Verified)	Enlisted Flyer	Age	0.027
Basal Cell Carcinoma (Verified and Suspected)	Enlisted Flyer	Age	0.043
Sun Exposure-Related Malignant Skin Neoplasms (Verified)	Enlisted Flyer	Age	0.020
Sun Exposure-Related Malignant Skin Neoplasms (Verified and Suspected)	Enlisted Flyer	Age	0.037
Malignant Systemic Neoplasms (Verified)	Enlisted Groundcrew	Race	0.045

*Refer to Table G-3 for a further investigation of these interactions.

Sun Exposure-Related Malignant Skin Neoplasms

The unadjusted analyses for the sun exposure-related malignant skin neoplasms, presented in Table 10-14, displayed similar patterns to basal cell carcinoma of borderline or significant differences among the enlisted flyer group. However, the differences were again due to higher frequencies found in the low exposure category. This observation parallels that seen for basal cell carcinoma since participants with basal cell tumors comprise 90 percent of the participants with sun exposure-related malignancies. For the verified set of sun exposure-related malignant skin neoplasms, there was a borderline significant difference in the Ranch Hand enlisted flyer frequencies (p=0.059) across exposure categories. The contrast for high versus low exposure was also borderline significant (p=0.098). No significant differences were found for the officers or enlisted groundcrew. For the verified and suspected set, the frequencies for the enlisted flyers differed significantly (p=0.028) across the exposure categories. However, the low exposure group again had the highest frequency. The borderline significant contrast of medium versus low exposure (p=0.062) had an estimated relative risk of 0.28 (95% C.I.: [0.09,0.96]). The contrast of high versus low exposure also had a borderline significant difference (p=0.060) with an estimated relative risk of 0.25 (95% C.I.: [0.07,0.96]).

For the adjusted exposure index analyses, Table 10-15 shows that for the Ranch Hand officers and enlisted groundcrew, there were no significant differences among the exposure levels for either the verified or the verified and suspected set of sun exposure-related malignant skin neoplasms. Table 10-16 summarizes significant exposure index-by-age interactions for the Ranch Hand enlisted flyers. There were significant exposure index-by-age interactions for the set of verified sun exposure-related malignant skin neoplasms (p=0.020), and verified and suspected sun exposure-related malignant skin neoplasms (p=0.037). Similar to the adjusted analyses for basal cell carcinoma, Appendix Table G-3 summarizes the results of stratifying the enlisted flyers by age for the set of sun exposure-related malignant skin neoplasms. For the verified, and verified and suspected, sun exposure-related malignant skin neoplasms, Ranch Hand enlisted flyers born prior to 1942 had significantly different relative frequencies of the skin neoplasms by exposure index (p=0.013 for verified sun exposure-related malignant skin neoplasms; p=0.005 for verified and suspected sun exposure-related malignant skin neoplasms). However, similar to basal cell carcinoma, the relative frequencies were inversely related to exposure index (i.e., the low exposure category had the highest relative frequency). Pairwise contrasts of the medium or high exposure levels with the low exposure level were also significant or borderline significant, although the differences were not consistent with a relationship of increasing exposure. For the enlisted flyer analyses having significant exposure index-by-age interactions, a second adjusted analysis was performed without this interaction. Table 10-15 presents the results of these secondary analyses. For verified sun exposure-related malignant skin neoplasms, the enlisted flyer group difference was significant (p=0.046). For verified and suspected sun exposure-related malignant skin neoplasms, the enlisted flyer group difference was also significant (p=0.017). Again, relative risks were not supportive of an increasing rate of sun exposure-related malignant skin neoplasms with increasing exposure.

Malignant Systemic Neoplasms

For each Ranch Hand occupational group, Table 10-14 summarizes the unadjusted analyses comparing the relative frequencies of verified malignant systemic neoplasms by exposure index. There were no significant differences across the exposure levels (officers: p=0.464; enlisted flyers: p=0.393; enlisted groundcrew: p=0.135). Table 10-14 presents comparisons only for verified malignant systemic neoplasms because there were no suspected malignant systemic neoplasms.

For malignant systemic neoplasms, Table 10-15 summarizes by occupation the adjusted exposure index analyses for the Ranch Hands. As noted above for the unadjusted analyses, there were no suspected malignant systemic neoplasms; therefore, adjusted analysis results were presented only for verified malignant systemic neoplasms.

Table 10-15 shows that for the Ranch Hand officers and enlisted flyers, there were no significant differences among the exposure levels for verified malignant systemic neoplasms (p=0.536 and p=0.225, respectively). However, for the enlisted groundcrew, there was a significant exposure index-by-race interaction (p=0.045), as presented in Table 10-16. For this interaction, the enlisted groundcrew results were stratified by race. The stratified results are presented in Appendix Table G-3. The overall comparison of the relative frequencies of verified malignant systemic neoplasms across exposure index levels was significant for the nonblack Ranch Hand enlisted groundcrew (p=0.046). Relative risks and confidence intervals for contrasts of the exposure index categories were not given due to sparse occurrence of malignant systemic neoplasms. For the enlisted groundcrew, a second adjusted analysis, presented in Table 10-15, was performed without this interaction. For this secondary analysis, the exposure index contrast was significant (p=0.024), but still not supportive of a dose-response relationship across the three exposure categories with higher rates in the medium exposure category.

Mortality and Malignant Neoplasm History

This section summarizes the survival status and malignant neoplasm history of the fully compliant Baseline participants through the 1987 followup examination. Survival status was determined through the end of 1987.

Of the 1,045 Ranch Hands and 1,224 Comparisons who were fully compliant at Baseline, 944 Ranch Hands (90.3%) and 1,113 Comparisons (90.9%) returned for the 1987 followup examination. Table 10-17 presents numbers of fully compliant Baseline Ranch Hands and Comparisons by participation/nonparticipation in the 1987 followup examination and by survival status at the end of 1987.

For the 101 Ranch Hands and 111 Comparisons who did not return for the 1987 followup examination, Table 10-18 shows that in 5 of the 20 deaths among Ranch Hands, malignant neoplasm was the primary cause of death. Of the five dead Ranch Hands, three died with lung cancer, one died with a malignant neoplasm of the pancreas, and one died with a histiocytoma of the lower limb.

TABLE 10-17.

Number of Fully Compliant Baseline Participants by
Participation at 1987 Followup Examination,
Survival Status, and Group

Participated in 1987 Followup Examination	Survival Status	Group		
		Ranch Hand	Comparison	Total
Yes	Dead[a]	2	2	4[b]
	Alive	942	1,111	2,053
No	Dead	20	29	49
	Alive	81	82	163
Total		1,045	1,224	2,269

[a]Died in 1987, but subsequent to participation in the 1987 followup examination.

[b]One Comparison died of malignant neoplasm of the lung; the other three deaths (two Ranch Hands, one Comparison) were not cancer-related.

Similarly, 11 of the 29 deaths among Comparisons had malignant neoplasm listed as the primary cause of death. Of the 11 dead Comparisons, 4 died with lung cancer, 4 with cancer of the colon, 1 had cancer of the stomach, 1 died with cancer of the mouth, and 1 died with cancer of the neck. One Ranch Hand died with a malignant neoplasm (basal cell carcinoma of the right temple) that was not the primary cause of death. The primary cause of death for the Ranch Hand was listed as "complications from thromboembolism following heart surgery."

Among the 81 surviving Ranch Hands who did not return for the 1987 followup, 5 Ranch Hands had verified malignant neoplasms at Baseline. Two of the five Ranch Hands had malignant neoplasms at multiple sites. One Ranch Hand was diagnosed as having basal cell carcinoma of the skin of the external ear, skin of the cheek, and skin of the nose; the other Ranch Hand had basal cell carcinoma of the skin of the forehead and skin of the external ear. For the other three Ranch Hands, the malignant neoplasms were an adenocarcinoma of the kidney, basal cell carcinoma of the skin of the forearm, and squamous cell carcinoma of the lower lip. In contrast, 4 of the 82 nonreturning but surviving Comparisons had a verified malignant neoplasm. Among the four Comparisons, one participant had basal cell carcinoma of the skin of the shoulder, skin of the neck, and skin of the back. One Comparison had a basal cell carcinoma of the skin of the external ear, and the other two Comparisons each had basal cell carcinoma of the skin of the nose.

TABLE 10-18.

**Fully Compliant Baseline Participants
Who Did Not Participate in the 1987 Followup Examination
by Survival Status and Group**

Survival Status	Group		Total
	Ranch Hand	Comparison	
Dead: Primary Cause of Death			
Malignant Neoplasm	5[a]	11[b]	16
Other Causes	15[c]	18	33
Alive			
Verified Malignant Neoplasm at Baseline	5[d]	4[e]	9
No Verified Malignant Neoplasm at Baseline	76	78	154

[a]Three Ranch Hands with lung cancer, one with malignant neoplasm of the pancreas, and one with histiocytoma of lower limb.

[b]Four Comparisons with lung cancer, four with cancer of the colon, one with cancer of the stomach, one with cancer of the mouth, and one with cancer of the neck.

[c]One Ranch Hand had a basal cell carcinoma of the right temple, which was not the primary cause of death. The primary cause of death was listed as "complications from thromboembolism following heart surgery."

[d]One Ranch Hand with basal cell carcinoma of the skin of the external ear, skin of the cheek, and skin of the nose; one with basal cell carcinoma of the skin of the forehead and skin of the external ear; one with adenocarcinoma of the kidney; one with basal cell carcinoma of the skin of the forearm; one with squamous cell carcinoma of the lower lip.

[e]One Comparison with basal cell carcinoma of the skin of the shoulder, skin of the neck, and skin of the back; two with basal cell carcinoma of the skin of the nose; and one with basal cell carcinoma of the skin of the external ear.

In summary, 11 of the 101 Ranch Hands (10.9%) not returning for the 1987 followup examination had incident or fatal neoplasms, compared to 15 of the 111 Comparisons (13.5%). This group difference was not significant (p=0.712).

For fully compliant Baseline participants who also attended the 1985 and the 1987 followup studies, Table 10-19 presents numbers and percentages of Ranch Hands and Comparisons having verified malignant skin neoplasms first diagnosed at the specified Baseline and/or 1985 followup, 1987 and/or followup examinations. Table 10-20 is a similar summary for the verified malignant systemic neoplasms.

TABLE 10-19.

Frequencies of Verified Malignant Skin Neoplasms[a] for
Participants at the Baseline, 1985, and 1987
Followup Examinations by Group

Presence of Neoplasm at Examination			Ranch Hand		Comparison	
Baseline	1985	1987	Number	Percent	Number	Percent
Yes	Yes	Yes	1	(0.1%)	1	(0.1%)
Yes	Yes	No	6	(0.7%)	7	(0.7%)
Yes	No	Yes	3	(0.3%)	7	(0.7%)
Yes	No	No	28	(3.2%)	30	(2.9%)
No	Yes	Yes	4	(0.5%)	0	(0.0%)
No	Yes	No	17	(2.0%)	24	(2.3%)
No	No	Yes	17	(2.0%)	18	(1.8%)
No	No	No	794	(91.3%)	941	(91.5%)
			870		1,028	

[a]Blacks excluded.

TABLE 10-20.

Frequencies of Verified Malignant Systemic Neoplasms for
Participants at the Baseline, 1985, and 1987
Followup Examinations by Group

Presence of Neoplasm at Examination			Ranch Hand		Comparison	
Baseline	1985	1987	Number	Percent	Number	Percent
Yes	Yes	Yes	0	(0.0%)	0	(0.0%)
Yes	Yes	No	0	(0.0%)	1	(0.1%)
Yes	No	Yes	0	(0.0%)	1	(0.1%)
Yes	No	No	10	(1.1%)	8	(0.7%)
No	Yes	Yes	0	(0.0%)	0	(0.0%)
No	Yes	No	2	(0.2%)	8	(0.7%)
No	No	Yes	8	(0.9%)	3	(0.3%)
No	No	No	904	(97.8%)	1,075	(98.1%)
			924		1,096	

DISCUSSION

In ambulatory medicine, the recommendation that asymptomatic individuals undergo periodic physical examinations is based largely on the assumption that such screening will reveal occult malignancy. Although the guidelines for the frequency and content of such examinations are subject to debate, there is no doubt that early detection affords the best and, in most forms of cancer, the only chance for cure. In this regard, while no one screening test is absolutely reliable, the scope and depth of the protocol employed in this longitudinal study far exceed what would be considered routine in clinical practice.

As the anatomic point of contact with industrial toxins and as the only organ system with a clearly defined clinical endpoint (chloracne) for TCDD exposure, the skin deserves the special emphasis it has received in this and in previous examination cycles. Though to date there is no epidemiologic evidence that TCDD exposure causes or that chloracne is associated with the development of basal cell carcinoma, an increased incidence of these skin cancers in the Ranch Hand cohort was found in the Baseline, and in the 1985 followup and 1987 followup examinations. Subsequent to the Baseline,

heightened efforts were made to clarify the contribution of such well-known risk factors as hair and eye color, complexion, ethnic background, and lifetime sun exposure.

While most of the systemic neoplasms subjected to analysis can be detected based on the history, physical examination, and laboratory data collected, several would require diagnostic studies beyond the scope of the current study. Reliably found on physical exam are tumors of the face, head and neck, oral cavity and pharynx (but not the hypopharynx or larynx), thyroid, prostate, and genitalia. The chest x ray can be relied upon to screen for tumors of the thymus, mediastinum, and lung, while the routine urinalysis, in disclosing hematuria, can signal the presence of kidney and bladder cancer. Recognizing the silent nature of digestive tract cancers, particularly those of colorectal origin, participants were encouraged to complete Hemoccult panels and, in positive cases, were offered sigmoidoscopy during their examinations.

Most of the significant dependent variable-covariate associations defined in these analyses would be expected based on patterns established in clinical practice. For basal cell skin cancers, positive associations were found with the classical risk factors of age, fair complexion, and average residential latitude.

Given the current knowledge of exposure levels in the Ranch Hand cohort, the higher frequency of basal cell carcinomas in the officers relative to the enlisted groundcrew (8.7% vs. 5.3%) does not provide evidence for the role of herbicides in the etiology of these cutaneous cancers. Of interest was the reduced frequency of basal cell cancer in those participants with the greatest skin sensitivity to sunlight, a finding that is consistent with behavior modification and exposure precaution in those most at risk.

In practice, dermatologists will vary in what they consider to be indications for the biopsy of suspicious lesions as called for in the study protocol. Acting independently and strictly blinded to the participants' exposure status, three dermatologists performed a total of 39 biopsies. As noted in Chapter 14, the close to equal number of biopsies in the Ranch Hands (19) and Comparisons (20) provides reassurance against the possibility of any significant selection bias in those lesions verified histologically.

With reference to the analysis of systemic neoplasms, the expected age-related increase in the incidence of cancer was documented in the total study population. The well-established clinical correlation of alcohol consumption with the development of systemic cancer was also observed (p=0.041). The Ranch Hand and the Comparison groups did not differ with respect to the frequency of systemic neoplasms. As in the Baseline and 1985 followup examinations, the relative frequency of verified cases of malignant systemic neoplasms did not differ significantly by group (2.1% in Ranch Hands, 1.6% in Comparisons). The number of cancers in specific categories was small and therefore statistical power to detect relative risks for specific cancers was low.

For the 1985 followup, one Ranch Hand and one Comparison had verified STS (fibrous histiocytoma and fibrosarcoma, respectively). The Ranch Hand was not part of the 1987 followup because he died; the Comparison with the fibro-

sarcoma was part of the 1987 followup. At the 1985 followup, one Ranch Hand was classified as a suspected leukemia, Hodgkin's Disease, or NHL. He was diagnosed as a verified leukemia by the time of the 1987 followup. At the 1987 followup, there was one verified case of NHL in a Ranch Hand.

In summary, the incidence of systemic cancer in all participants enrolled in this longitudinal study remains similar to the general population. As in the 1985 examination cycle, basal cell skin cancer appears to occur more frequently in the Ranch Hand cohort. With respect to systemic cancers, the Ranch Hand and Comparison group frequencies did not differ significantly. As in the past, no significant difference in cancer-related mortality was found between the study groups. To date, there has been one death in the Ranch Hand group related to soft tissue malignancy. One individual in the Comparison group has this diagnosis, but is still alive.

SUMMARY

For the 1987 followup analyses of skin neoplasms, a number of unadjusted analyses were performed to compare the Ranch Hand and Comparison groups on specified sets of verified skin malignancies and specified sets of verified and suspected skin malignancies. Selected adjusted analyses, which accounted for effects of specified covariates, were also undertaken. Table 10-21 summarizes the outcomes of the various unadjusted and adjusted analyses that were performed for the skin neoplasm assessment.

The unadjusted analyses of verified malignant skin neoplasms indicated a significant difference between the Ranch Hand and Comparison relative frequencies (p=0.047). For the verified and suspected malignant skin neoplasms, the relative frequencies for the Ranch Hands and Comparisons did not differ significantly (p=0.101). Unadjusted analyses of both the benign skin neoplasms and skin neoplasms of uncertain behavior or unspecified nature did not display significant group differences. Analyzing all skin neoplasms, (i.e., including the benign skin neoplasms and skin neoplasms of uncertain behavior or unspecified nature), unadjusted analyses indicated significant group differences at the 1987 followup (p=0.012 for the verified set; p=0.029 for the verified and suspected set).

For the 1987 followup, unadjusted analyses were performed comparing the Ranch Hands and Comparisons on their relative frequencies of basal cell carcinoma, squamous cell carcinoma, melanoma, and sun exposure-related malignant skin neoplasms. For basal cell carcinoma, there was a borderline significant unadjusted group difference for the verified set (p=0.076), and there was no significant difference for the verified and suspected set. Following adjustment by covariates, the group contrast for the verified set of basal cell carcinoma was significant (p=0.030). The adjusted group contrast for the verified and suspected set of basal cell carcinoma was borderline significant (p=0.053). At Baseline, a significantly higher rate of verified basal cell carcinoma was found for Ranch Hands in the unadjusted analysis. For the 1985 followup, the adjusted analysis of verified basal cell carcinoma displayed a significant group difference and the unadjusted analysis did not exhibit a significant group difference.

TABLE 10-21.

Overall Summary Results of Unadjusted and Adjusted Group Contrast Analyses of Malignancy Variables

Variable	Verification Status	Unadjusted	Adjusted	Direction of Results
Skin Neoplasms				
Behavior				
Malignant	V	0.047	--	$RH > C^d$
	VS	NS	--	
Benign	V^a	NS	--	
Uncertain Behavior or Unspecified Nature	V	NS	--	
	VS	NS	--	
All	V	0.012	--	$RH > C_d$
	VS	0.029	--	$RH > C^d$
Cell Type				
Basal Cell Carcinoma	V	NS*	0.030	$RH > C^d$
	VS	NS	NS*	$RH > C^d$
Squamous Cell Carcinoma	V^a	NS	--	
Melanoma	V^a	NS	--	
Sun Exposure-Related Malignant Skin Neoplasm	V	0.042	0.019	$RH > C^d$
	VS	NS*	0.044	$RH > C^d$
Basal Cell Carcinoma by Location/Site				
Ear, Face, Head, and Neck	V	NS	--	
	VS	NS	--	
Trunk	V	NS	--	
	VS	NS	--	
Upper Extremities	V^a	NS	--	
Lower Extremities	V^a	$--^b$	--	
Other Sites and Sites NOS	V	NS	--	
	VS	NS	--	

TABLE 10-21. (continued)

**Overall Summary Results of Unadjusted and Adjusted
Group Contrast Analyses of Malignancy Variables**

Variable	Verification Status	Unadjusted	Adjusted	Direction of Results
Melanoma by Location/Site				
Ear, Face, Head, and Neck	V[a]	NS	--	
Trunk	V[a]	NS	--	
Upper Extremities	V[a]	--[b]	--	
Lower Extremities	V[a]	--[b]	--	
Other Sites and Sites NOS	V[a]	--[b]	--	
Sun Exposure-Related Malignant Skin Neoplasms by Location/Site				
Ear, Face, Head, and Neck	V	NS	--	
	VS	NS	--	
Trunk	V	NS	--	
	VS	NS	--	
Upper Extremities	V[a]	0.044	--	RH>C[d]
Lower Extremities	V	--[b]	--	
Other Sites and Sites NOS	V	NS	--	
	VS	NS	--	
Basal Cell Carcinoma of the Ear, Face, Head and Neck by Occupation				
Officer	V	NS	--	
	VS	NS	--	
Enlisted Flyer	V	NS	--	
	VS	NS	--	
Enlisted Groundcrew	V	NS	--	
	VS	NS	--	

TABLE 10-21. (continued)

**Overall Summary Results of Unadjusted and Adjusted
Group Contrast Analyses of Malignancy Variables**

Variable	Verification Status	Unadjusted	Adjusted	Direction of Results
Sun Exposure-Related Malignant Skin Neoplasms of the Ear, Face, Head, and Neck by Occupation				
Officer	V	NS*	--	RH>C[d]
	VS	NS	--	
Enlisted Flyer	V	NS	--	
	VS	NS	--	
Enlisted Groundcrew	V	NS	--	
	VS	NS	--	
Conditional Analyses				
Skin Neoplasm Conditioned on Neoplasm	V	NS*	--	RH>C[d]
	VS	NS*	--	RH>C[d]
Malignant Skin Conditioned on Skin Neoplasm	V	NS	--	
	VS	NS	--	
Basal Cell Carcinoma Conditioned on Malignant Skin Neoplasm	V	NS	--	
	VS	NS	--	
Basal Cell Carcinoma of Ear, Face, Head, and Neck Conditioned on Basal Cell Carcinoma	V	NS	--	
	VS	NS	--	
Sun Exposure-Related Malignant Skin Neoplasm of Ear, Face, Head, and Neck Conditioned on Sun Exposure-Related Malignant Skin Neoplasm	V	NS	--	
	VS	NS	--	
Multiple Basal Cell Carcinoma				
Zero, One, or Multiple	V	0.050	--	RH>C[d]
	VS	NS	--	
One vs. Zero	V	NS	--	
	VS	NS	--	
Multiple vs. Zero	V	0.032	--	RH>C[d]
	VS	NS*	--	RH>C[d]

TABLE 10-21. (continued)

**Overall Summary Results of Unadjusted and Adjusted
Group Contrast Analyses of Malignancy Variables**

Variable	Verification Status	Unadjusted	Adjusted	Direction of Results
Systemic Neoplasms				
Behavior				
Malignant	V	NS	NS	
	VS	NS	NS	
Benign	V	NS	--	
	VS	NS	--	
Uncertain Behavior or Unspecified Nature	V	NS	--	
	VS	NS	--	
All	V	NS	--	
	VS	NS	--	
Malignant Systemic Neoplasms by Location/Site				
Oral Cavity, Pharynx, and Larynx	V[a]	NS	--	
Thyroid	V[a]	NS	--	
Bronchus and Lung	V	NS	--	
	VS	NS	--	
Colon and Rectum	V[a]	NS	--	
Kidney and Bladder	V[a]	NS	--	
Prostate	V[a]	NS	--	
Testicles	V[a]	NS	--	
Hodgkin's Disease	V[a]	NS	--	
Ill-Defined Sites	VS[c]	NS	--	
Thymus and Mediastinum	V[a]	NS	--	
Head, Face, and Neck	V[a]	NS	--	

TABLE 10-21. (continued)

Overall Summary Results of Unadjusted and Adjusted
Group Contrast Analyses of Malignancy Variables

Variable	Verification Status	Unadjusted	Adjusted	Direction of Results
Malignant Systemic Neoplasms by Location/Site (continued)				
Brain	V[a]	NS	--	
Other Malignant Neoplasms of Lymphoid and Histiocytic Tissue	V[a]	NS	--	
Leukemia	V[a]	NS	--	
Carcinoma In Situ of Penis	V[a]	NS	--	
Carcinoma In Situ of Other Specified Sites	V[a]	NS	--	
Conditional Analyses				
Malignant Systemic Neoplasm	V	NS	--	
Conditioned on All Systemic	VS	NS	--	
Skin and Systemic				
All Skin and Systemic	V	0.032	--	RH>C[d]
Neoplasms Combined	VS	NS*	--	RH>C[d]
Nonverifiable Neoplasm	--	NS	--	

V: Verified neoplasms.
--Analysis not performed or not applicable.
RH>C: Larger incidence in Ranch Hands.
VS: Verified and suspected neoplasms.
NS: Not significant (p>0.10).
[a]No suspected neoplasms.
NS*: Borderline significant (0.05<p≤0.10).
[b]No neoplasms for either Ranch Hands or Comparisons.
[c]No verified neoplasms.
[d]These group contrasts are related. For example, basal cell carcinoma is part of the sun exposure-related malignant skin neoplasms, and the sun exposure-related malignant skin neoplasms are part of the malignant skin neoplasms, which are part of all skin neoplasms.

The group contrast for the unadjusted analyses of sun exposure-related malignant skin neoplasms was significant for the verified set (p=0.042) and borderline significant for the verified and suspected set (p=0.081). Covariate adjustment analyses produced significant group contrasts (p=0.019 and p=0.044, respectively).

The unadjusted group contrast analyses for squamous cell carcinoma and melanoma were not significant.

Unadjusted analyses comparing the Ranch Hand and Comparison groups on relative frequency of basal cell carcinoma, melanoma, and sun exposure-related malignant skin neoplasms by anatomical location/site were also performed. For sun exposure-related malignant skin neoplasms, Ranch Hands and Comparisons differed for malignancies of the upper extremities (p=0.044 for the verified set; there were no suspected malignant neoplasms at this site). No other significant differences were found at the sites of interest for the sun exposure-related malignant skin neoplasms, or for any of these sites for basal cell carcinoma or melanoma.

Unadjusted group comparisons were performed comparing the frequencies of basal cell carcinoma and sun exposure-related malignant skin neoplasms occurring on the ear, face, head, and neck by occupation. For basal cell carcinoma (both the verified set and the verified and suspected set), there were no significant group differences for any occupation. For sun exposure-related malignant skin neoplasms, the officers exhibited a borderline significant group difference (p=0.078) for the verified set. For these unadjusted analyses, there were no other significant differences for sun exposure-related malignant skin neoplasms.

The following conditional unadjusted analyses of relative frequencies were performed for the Ranch Hand and Comparison groups: skin neoplasm conditioned on the presence of any neoplasm; malignant skin neoplasm conditioned on the presence of any skin neoplasm; basal cell carcinoma conditioned on the presence of a malignant skin neoplasm; basal cell carcinomas of the ear, face, head, neck, or upper extremities conditioned on the presence of basal cell carcinoma; and sun exposure-related malignant skin neoplasms of the ear, face, head, neck, or upper extremities conditioned on the presence of sun exposure-related malignant skin neoplasms. Conditioned on the presence of a neoplasm, the Ranch Hand and Comparison percentages of skin neoplasms were marginally significantly different (p=0.095 for the verified set of neoplasms; p=0.100 for the verified and suspected set of neoplasms). None of the other conditional analyses exhibited significant group differences.

The Ranch Hand and Comparison groups were also compared on the distributions of participants with zero, one, or multiple basal cell carcinomas. For the verified set, there was a significant group difference (p=0.050). For the verified and suspected set of basal cell carcinoma, the Ranch Hand and Comparison groups did not differ significantly on the frequency of participants with zero, one, or multiple basal cell carcinoma. Contrasting 1987 followup participants with zero basal cell carcinomas versus multiple basal cell carcinomas, the groups differed on their relative frequencies (p=0.032) for the verified set. For the verified and suspected set, the groups were borderline significantly different (p=0.069). For the 1985

10-81

followup, the group contrasts for none versus multiple basal cell carcinomas were not significant.

Table 10-21 also summarizes the results of the unadjusted and adjusted analyses performed for the systemic neoplasm assessment. Unadjusted analyses comparing the Ranch Hands and Comparisons on their relative frequencies of systemic neoplasms by behavior (malignant, benign, and uncertain behavior or unspecified nature) and all systemic neoplasms were not significant. Analyses of malignant systemic neoplasms adjusting for covariate information also indicated no significant differences between the Ranch Hands and Comparisons.

For specified locations/sites, Ranch Hands and Comparisons did not differ with respect to their relative frequencies of malignant systemic neoplasms. Ranch Hands and Comparisons also did not differ on their relative frequencies of malignant systemic neoplasms conditioned on the occurrence of a systemic neoplasm.

Table 10-21 also presents the results of unadjusted analyses for the combined set of all skin and systemic neoplasms. For the combined set of verified skin and verified systemic neoplasms, the Ranch Hand and Comparison 1987 followup groups differed significantly (p=0.032). For the verified and suspected combined set of skin and systemic neoplasms, the Ranch Hand and Comparison 1987 followup groups were borderline significant (p=0.079). This difference is due to the previously described group difference in skin malignancy. Table 10-21 also presents the results of unadjusted analyses comparing Ranch Hands and Comparisons on the frequency of nonverifiable skin and systemic neoplasms. No significant group difference was found.

The statistical power for detecting group differences on the frequency of systemic neoplasms at specified sites is low. The statistical power of the systemic neoplasm analyses improved somewhat when malignancies were aggregated across sites. Statistical power was strongest for the aggregated skin neoplasm analyses.

The frequency of basal cell carcinomas and sun exposure-related malignant skin neoplasms in the Ranch Hand group was compared across exposure index categories within each occupation strata. For the unadjusted analyses of basal cell carcinomas, there was a borderline significant difference among enlisted flyers for the verified set (p=0.067) and a significant difference among enlisted flyers for the verified and suspected (p=0.031) basal cell carcinomas. For adjusted analyses, significant exposure index-by-age interactions were present among the enlisted flyers for both sets of basal cell carcinomas. Analysis of the exposure index data within age strata did not support a dose-response relationship. For the unadjusted analyses of sun exposure-related malignant skin neoplasms, there was a borderline significant difference among enlisted flyers for the verified set (p=0.059) and a significant difference among enlisted flyers for the verified and suspected set (p=0.028). Again adjusting for covariate information resulted in significant exposure index-by-age interactions for both sets of sun exposure-related malignant skin neoplasms for the enlisted flyers. Results of stratified analyses did not support a dose-response relationship. No other significant differences were found for the exposure index analyses of these skin neoplasms.

The frequency of verified systemic malignant neoplasms in the Ranch Hand group was compared across exposure index categories within each occupation strata. For the unadjusted exposure index analyses, there were no significant differences by occupation. For the officers and enlisted flyers, the adjusted analyses were nonsignificant. However, there was a significant exposure index-by-race interaction for the enlisted groundcrew. Comparing the relative frequencies of systemic neoplasms across exposure levels within each race category for the enlisted groundcrew produced a significant difference for the nonblack Ranch Hands (p=0.046). However, the results from analyses stratified by race did not support a dose-response relationship (the midrange exposure group had more malignancies than either the low or high strata).

Table 10-22 displays the unadjusted relative risks for verified basal cell carcinoma at the Baseline, 1985 followup, and 1987 followup examinations. Ranch Hands showed a higher frequency of basal cell carcinoma than the Comparisons, a finding also noted at Baseline and the 1985 followup.

In addition to the higher frequency of basal cell carcinoma, Ranch Hands had a greater relative frequency of multiple basal cell carcinomas than the Comparisons at the 1987 followup. Sun exposure-related malignant skin neoplasms also exhibited an increased frequency for the Ranch Hands relative to the Comparisons. The increase was not surprising because the majority of the sun exposure-related malignancies were basal cell carcinomas. Ranch Hands and Comparisons did not differ significantly for systemic neoplasms. There has been one case of soft tissue sarcoma in both the Ranch Hand and the Comparison groups (both described in the report of the 1985 physical examination) and one case of Hodgkin's lymphoma in a Ranch Hand. The results of the exposure index analyses were not supportive of a dose-response relationship.

TABLE 10-22.

Unadjusted Analyses of Verified Basal Cell Carcinoma at Baseline, 1985 Followup, and 1987 Followup Examinations

Number of Participants[d] With Neoplasms/Percent	Baseline[a]	1985 Followup[b]	1987 Followup[c]
Ranch Hand	31 3.0%	53 5.5%	78 8.3%
Comparison	21 1.7%	50 4.1%	76 6.2%
Est. Relative Risk	1.71	1.36	1.36
p-Value	0.047[e]	0.128[e,f]	0.076[e,f]

[a]Baseline participants: 1,045 Ranch Hands, 1,224 Comparisons.

[b]1985 followup participants: 1,016 Ranch Hands, 1,293 Comparisons.

[c]1987 followup participants: 995 Ranch Hands, 1,299 Comparisons.

[d]Nonblacks only for the 1985 followup (956 Ranch Hands, 1,210 Comparisons); nonblacks only for the 1987 followup (938 Ranch Hands, 1,219 Comparisons); both nonblacks and Blacks for the Baseline.

[e]Baseline p-value based on chi-square test; 1985 and 1987 followup p-values based on Fisher's exact test.

[f]Adjusted analyses performed for the 1985 and 1987 followups produced the following estimated relative risks and associated p-values: 1.56 (p=0.035) and 1.46 (p=0.030), respectively.

CHAPTER 10

REFERENCES

1. Poland, A. 1984. Reflections on the mechanism of action of halogenated aromatic hydrocarbons. In Banbury report 18: Biological mechanisms of dioxin action, ed. A. Poland and R.D. Kimbrough, pp. 109-117. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.

2. Goldstein, J.A., M.J. Graham, T. Sloop, R. Maronpot, T. Goodrov, and G.W. Lucier. 1987. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on enzyme-altered foci, hepatocellular tumors, and estradiol metabolism in a two-stage hepatocarcinogenesis model. Abstract of a paper presented at the 7th International Symposium on Chlorinated Dioxins and Related Compounds, Las Vegas, Nevada, October 4-9, 1987, pp. 148-149.

3. Graham, M.J., G.W. Lucier, U. Rickenbacher, and J.A. Goldstein. 1987. Induction of rat hepatic microsomal estradiol 2-hydroxylase (E2-OHase) activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Fed. Proc. 46:379.

4. Sleight, S.D., R.K. Jensen, and M.S. Rezabek. 1987. Enhancement of hepatocarcinogenesis in rats by simultaneous administration of 2,4,5,2',4',5' hexachlorobiphenyl (HCB) and 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD). Abstract of a paper presented at the 26th Annual Meeting of the Society of Toxicology. The Toxicologist 7:103.

5. Busser, M.T., and W.K. Lutz. 1987. Stimulation of DNA synthesis in rat and mouse liver by various tumor promoters. Carcinogenesis 8:1433-1437.

6. Clement Associates, Inc. 1987. Review of literature on herbicides including phenoxy herbicides and associated dioxins, vol. XI. Veterans Administration, Washington, DC.

7. DiGiovanni, J., A. Viaje, D.L. Berry, T.J. Slaga, and M.R. Juchau. 1977. Tumor initiating ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Aroclor 1254 in a two-stage system of mouse skin carcinogenesis. Bull. Environ. Contam. Toxicol. 18:522-557.

8. Berry, D.L., T.J. Slaga, J. DiGiovanni, and M.R. Juchau. 1979. Studies with chlorinated dibenzo-p-dioxins, polybrominated biphenyls and polychlorinated biphenyls in a two-stage system of mouse skin tumorigenesis: Potent anticarcinogenic effects. Ann. N.Y. Acad. Sci. 320:405-414.

9. National Toxicology Program (NTP). 1982. Carcinogenesis bioassay of 2,3,7,8-tetrachlorodibenzo-p-dioxin (CAS no. 1746-01-6) in Swiss-Webster mice (dermal study). Report 80-32, technical report series no. 201, NIH publication no. 82-1757, Research Triangle Park, North Carolina.

10. Poland, A., D. Palen, and E. Glover. 1982. Tumor promotion by TCDD in skin of HRS/J hairless mice. Nature 300:271-273.

11. Kociba, R.J., D.G. Keyes, J.E. Beyer, R.M. Carreon, C.E. Wade, D.A. Dittenber, R.P. Kalnins, L.E. Frauson, C.N. Park, S.D. Barnard, R.A. Hummel, and C.G. Humiston. 1978. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 46:279-303.

12. National Toxicology Program (NTP). 1982. Carcinogenesis bioassay of 2,3,7,8-tetrachlorodibenzo-p-dioxin (CAS no. 1746-01-6) in Osborne-Mendel rats and B6C3F1 mice (gavage study). Report 80-31, technical report series no. 209, NIH publication no. 82-1765, Research Triangle Park, North Carolina.

13. Pitot, H.C., T. Goldsworthy, H.A. Campbell, and A. Poland. 1980. Quantitative evaluation of the promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin of hepatocarcinogenesis from diethylnitrosamine. Cancer Res. 40:3616-3620.

14. Romkes, M., J. Piskorska-Pliszczynska, and S. Safe. 1987. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and uterine estrogen receptor levels in rats. Toxicol. Appl. Pharmacol. 87:306-314.

15. Goldstein, J.A., M.J. Graham, R.R. Maronpot, T.L. Goodrow, and G.W. Lucier. 1988. Possible role of estrogen in promotion of liver carcinogenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Proc. Am. Assoc. Cancer Res. Annu. Meet. 29(0):154.

16. Geirthy, J.F., D.W. Lincoln II, S.J. Kampcik, H.W. Dickerman, H.L. Bradlow, T. Niwa, and G.E. Swaneck. 1988. Enhancement of 2- and 16 α-estradiol hydroxylation in MCF-7 human breast cancer cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Biophys. Res. Commun. 157(2):515-520.

17. Ivy, S.P., A. Tulpule, C.R. Fairchild, S.D. Averbuch, C.E. Myers, D.W. Nebert, W.M. Baird, and K.H. Cowan. 1988. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J. Biol. Chem. 263(35):19119-19125.

18. Geirthy, J.F., D.W. Lincoln II, M.B. Gillespie, J.I. Seeger, H.L. Martinez, H.W. Dickerman, and S.A. Kumar. 1987. Suppression of estrogen-regulated extracellular tissue plasminogen activator activity of MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 47(23):6198-6203.

19. Sundell, L., M. Rehn, and O. Axelson. 1974. Exposure to herbicides-- mortality and tumor incidence: An epidemiological investigation in Swedish railway workers. Lakartidningen 71:2466-2470.

20. Axelson, O., and L. Sundell. 1974. Herbicide exposure, mortality, and tumor incidence. An epidemiological investigation on Swedish railroad workers. Work Environ. Health 11:21-28.

21. Axelson, O., and L. Sundell. 1977. Phenoxy acids and cancer. Lakartidningen 74:2887-2888.

22. Axelson, O., L. Sundell, K. Andersson, C. Edling, C. Hogstedt, and H. Kling. 1980. Herbicide exposure and tumor mortality: An updated epidemiological investigation on Swedish railroad workers. Scand. J. Work Environ. Health 6:73-79.

23. Huff, J.E., J.A. Moore, R. Saracci, and L. Tomatis. 1980. Long-term hazards of polychlorinated dibenzodioxins and polychlorinated dibenzofurans. Environ. Health Perspect. 36:221-240.

24. Hardell, L. 1977. Malignant mesenchymal tumors and exposure to phenoxy acids: A clinical observation. Lakartidningen 74:542-546.

25. Hardell, L. 1977. Soft-tissue sarcomas and exposure to phenoxyacetic acids and cancer. Lakartidningen 74:2735.

26. Hardell, L. 1979. Malignant lymphoma of histiocytic type and exposure to phenoxyacetate or chlorophenols. Lancet I:55-56.

27. Hardell, L., M. Eriksson, P. Lenner, and E. Lundgren. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: A case control study. Br. J. Cancer 43:169-176.

28. Eriksson, M., L. Hardell, N.O. Berg, T. Moller, and O. Axelson. 1981. Soft tissue sarcomas and exposure to chemical substances: A case-referent study. Br. J. Ind. Med. 38:27-33.

29. Hardell, L. 1981. Relation of soft-tissue sarcoma, malignant lymphoma and colon cancer to phenoxy acids, chlorophenols and other agents. Scand. J. Work Environ. Health 7:119-130.

30. Hardell, L., B. Johansson, and O. Axelson. 1982. Epidemiological study of nasal and nasopharyngeal cancer and their relation to phenoxy acid or chlorophenol exposure. Am. J. Indus. Med. 3:247-257.

31. Hardell, L., N.O. Bengtsson, U. Jonsson, S. Eriksson, and L.G. Larsson. 1984. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria--an epidemiological investigation. Br. J. Cancer 50:389-397.

32. Hardell, L., and O. Axelson. 1984. Phenoxy herbicides and other pesticides in the etiology of cancer: Some comments on the Swedish experience. Presented at Cancer Prevention--Strategies in the Workplace. University of California, San Francisco, December 1984.

33. Jannerfeldt, E. 1980. Epidemiological methodology and pesticide studies. Lakartidningen 77(12):1096.

34. (Editorial.) 1982. Phenoxy herbicides, trichlorophenols, and soft-tissue sarcomas. Lancet 1(8278):1051-1052.

35. Coggon, D., and E.D. Acheson. 1982. Do phenoxy herbicides cause cancer in man? Lancet 1(8278):1057-1059.

36. Axelson, O. 1978. Aspects on confounding in occupational health epidemiology, Letter. Scand. J. Work Environ. Health 4:85-89.

37. Axelson, O. 1980. Views on criticism of pesticide studies. Lakartidningen 77(12):1096-1099.

38. Axelson, O. 1980. A note on observational bias in case-referent studies in occupational health epidemiology. Scand. J. Work Environ. Health 6:80-82.

39. Remington, R.D. 1980. Specific summary critique of five investigations related to concerns about Agent Orange. Congressional Record, August 6, 1980, pp. S 10911, S 10912.

40. U.S. Environmental Protection Agency. 1985. Health assessment document for polychlorinated dibenzo-p-dioxins. Final report, September 1985.

41. Ott, M.G., B.B. Holder, and R.D. Olson. 1980. A mortality analysis of employees engaged in the manufacture of 2,4,5-trichlorophenoxyacetic acid. J. Occup. Med. 22:47-50.

42. Cook, R.R., J.C. Townsend, M.G. Ott, and L.G. Silverstein. 1980. Mortality experience of employees exposed to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD). J. Occup. Med. 22:530-532.

43. Zack, J.A., and R.R. Suskind. 1980. The mortality experience of workers exposed to tetrachlorodibenzo-dioxin in a trichlorophenol process accident. J. Occup. Med. 22:11-44.

44. Zack, J.A., and W.R. Gaffey. 1983. A mortality study of workers employed at the Monsanto Company Plant in Nitro, West Virginia. Environ. Sci. Res. 26:575.

45. Honchar, P.A., and W.E. Halperin. 1981. 2,4,5-T, trichlorophenol, and soft-tissue sarcoma. Lancet 1(8214):268-269.

46. Cook, R.R. 1981. Dioxin, chloracne, and soft-tissue sarcoma. Lancet 1(8220):618-619.

47. Moses, M., and I.J. Selikoff. 1981. Soft-tissue sarcomas, phenoxy herbicides, and chlorinated phenols. Lancet 1(8234):1370.

48. Johnson, F.E., M.A. Kugler, and S.M. Brown. 1981. Soft tissue sarcomas and chlorinated phenols. Lancet 2(8236):40.

49. Fingerhut, M.A., W.E. Halperin, P.A. Honchar, A.B. Smith, D.H. Groth, and W.O. Russell. 1984. An evaluation of reports of dioxin exposure and soft tissue sarcoma pathology in U.S. chemical workers. In Banbury report 18: Biological mechanisms of dioxin action, ed. A. Poland and R. D. Kimbrough, pp. 461-470. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.

50. Percy, C., E. Stanek, and L. Gloeckler. 1981. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am. J. Public Health 71(3):242-250.

51. Sobel, W., G.G. Bond, B.J. Skowronski, P.J. Brownson, and R.R. Cook. 1986. A soft tissue sarcoma case control study in large multi-chemical manufacturing facility. Paper presented at the 6th International Symposium on Chlorinated Dioxins and Related Compounds. Fukuoka, Japan, September 16-19, 1986.

52. Cook, R.R., G.G. Bond, R.A. Olson, and M.G. Ott. 1986. Update of mortality experiences of workers exposed to chlorinated dioxins. Abstract of paper presented at the 6th International Symposium on Chlorinated Dioxins and Related Compounds. Fukuoka, Japan, September 16-19, 1986.

53. Lehnert, G., and D. Szadkowski. 1985. The carcinogenicity of 2,3,7,8-TCDD in humans: Evaluation of liability. Arbeitsmed. Sozialmed. Praventivmed. 20:225-232.

54. Donna, A., P.G. Betta, F. Robutti, P. Crosignani, F. Berrino, D. Bellingeri. 1984. Ovarian mesothelial tumors and herbicides: A case-control study. Carcinogenesis 5:941-942.

55. Riihimaeki, V., S. Asp, E. Pukklala, and S. Hernberg. 1983. Mortality and cancer morbidity among chlorinated phenoxy acid applicators in Finland. Chemosphere 12:779-784.

56. Lynge, E. 1985. A follow-up study of cancer incidence among workers in manufacture of phenoxy herbicides in Denmark. Br. J. Cancer 52:259-270.

57. Smith, A.H., N.E. Pearce, D.O. Fisher, H.J. Giles, C.A. Teague, and J.K. Howard. 1984. Soft-tissue sarcoma and exposure to phenoxy herbicides and chlorophenols in New Zealand. JNCI 73:1111-1117.

58. Pearce, N.E., A.H. Smith, and D.O. Fisher. 1985. Malignant lymphoma and multiple myeloma linked with agricultural occupations in a New Zealand cancer registry-based study. Am. J. Epidemiol. 121:225-237.

59. Pearce, N.E., R.A. Sheppard, A.H. Smith, and C.A. Teague. 1987. Non-Hodgkin's lymphoma and farming: An expanding case-control study. Int. J. Cancer 39:155-161.

60. Wiklund, K., and L.E. Holm. 1986. Soft tissue sarcoma risk in Swedish agricultural and forestry workers. JNCI 76(2):229-234.

61. Hoar, S.K., A. Blair, F.F. Holmes, C.D. Boysen, R.J. Robel, R. Hoover, and J.F. Fraumeni, Jr. 1986. Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. JAMA 256:1141-1147.

62. Colton, T. 1986. Herbicide exposure and cancer. Editorial. JAMA 256:1176-1178.

63. Woods, J.S., L. Polissar, R.K. Severson, L.S. Heuser, and B.G. Kulander. 1987. Soft tissue sarcoma and non-Hodgkin's lymphoma in relating to phenoxy herbicide and chlorinated phenol exposure in western Washington. Preprint. JNCI 78:899-910.

64. Sarma, P.R., and G. Jacobs. 1981. Thoracic soft-tissue sarcoma in Vietnam veterans exposed to Agent Orange. New Engl. J. Med. 306(18):1109.

65. Greenwald, P., B. Kovasznay, D.N. Collins, and G. Therriault. 1984. Sarcomas of soft tissue after Vietnam service. JNCI 73:1107-1109.

66. Kogan, M.D., and R.W. Clapp. 1985. Mortality among Vietnam veterans in Massachusetts, 1972-1983. Boston, Massachusetts: Division of Health Statistics and Research, Massachusetts Department of Public Health.

67. Royal Commission on the Use and Effects of Chemical Agents on Australian Personnel in Vietnam. 1985. Cancer. Vol. 4 in Final Report, pp. VIII-129. Canberra, Australia: Australian Government Publishing Service.

68. Lawrence, C.E., A.A. Reilly, P. Quickenton, P. Greenwald, W.F. Page, A.J. Kuntz. 1985. Mortality patterns of New York State Vietnam veterans. Am. J. Public Health 75:277-279.

69. Wendt, A.S. 1985. Agent Orange Iowa survey of Vietnam veterans. Final Report, Iowa State Department of Health, July 1985.

70. Holmes, A.P. 1986. West Virginia Vietnam-era veterans mortality study. Preliminary report, Health Statistics Center, West Virginia Department of Health, January 1986.

71. Anderson, H.A., L.P. Hanrahan, M. Jensen, D. Laurin, W. Yick, and P. Wirgman. 1986. Wisconsin Vietnam veteran mortality study. Final report, Wisconsin Department of Health and Social Services, March 1986.

72. Kang, H.K., L. Weatherbee, P.P. Breslin, Y. Lee, and B.M. Shepard. 1986. Soft tissue sarcomas and military service in Vietnam: A case comparison group analysis of hospital patients. J. Occup. Med. 28:1215-1218.

73. Thiess, A.M., R. Frentzel-Beyme, and R. Link. 1982. Mortality study of persons exposed to dioxins in a trichlorophenol process accident that occurred in the BASF AG on November 17, 1953. Am. J. Ind. Med. 3:179-189.

74. Blair, A., D.J. Grauman, J.H. Lubin, and J.F. Fraumeni, Jr. 1983. Lung cancer and other causes of death among licensed pesticide applicators. JNCI 71:31-37.

75. Barthel, E. 1981. Cancer risk in agricultural workers exposed to pesticides. Arch. Geschwulstforsch. 51(7):579-585.

76. Gatti, R.A., and R.A. Good. 1971. Occurrence of malignancy in immuno-deficiency diseases: A literature review. Cancer 28:89-98.

77. Louie, S. and R.S. Schwartz. 1978. Immunodeficiency and the patho-
    genesis of lymphoma and leukemia. Semin. Hematol. 15:117-138.

78. Di Carlo, E.F., J.B. Amberson, C.E. Metroka, P. Ballard, A. Moore,
    J.A. Mouradian. 1986. Malignant lymphomas and the acquired immuno-
    deficiency syndrome. Arch. Pathol. Lab. Med. 110:1012-1016.

79. Lathrop, G.D., P.M. Moynahan, R.A. Albanese, and W.H. Wolfe. 1983.
    Epidemiologic investigation of health effects in Air Force personnel
    following exposure to herbicides: Baseline mortality study results,
    NTIS: AD A 130 793. USAF School of Aerospace Medicine, Epidemiology
    Division, Data Sciences Division, Brooks Air Force Base, Texas.

80. Scotto, J. and T.R. Fears. "Skin Cancer Epidemiology: Research Needs,"
    National Cancer Institute Monograph 50:169-177, 1978.

81. Holman, C.D.J., and B.K. Armstrong. "Pigmentary Traits, Ethnic Origin,
    Benign Nevi, and Family History as Risk Factors for Cutaneous
    Malignant Melanoma." JNCI 72:257-266, 1984.